3 Bargain Bin Stocks with Millionaire-Maker Potential
- There are three main drivers of a stock's return: growth, the change in price-to-earnings (P/E) multiple and capital return. While investors often focus on the growth angle, an upward rating in multiple can also be a significant return driver for bargain stocks.
- 07/09/2024
|
Baxter (BAX) Recovers After Life2000 Ventilation Systems Recall
- Shares of Baxter International BAX have gained 2.8% since Jun 26, after the company announced the recall of its Life2000 Ventilation System. Though the share price had declined following the news, it recovered following reports of potential discussion on divestment of BAX's kidney care segment.
- 07/08/2024
|
Reasons to Retain Baxter International (BAX) in Your Portfolio Now
- Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.
- 07/01/2024
|
Here's Why Baxter International (BAX) is a Strong Value Stock
- Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
- 06/10/2024
|
Baxter to Present at Goldman Sachs 45th Annual Global Healthcare Conference
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024. Joel Grade, Baxter's chief financial officer, is scheduled to present at 8:40 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Monday, December 9, 2024. About Baxter Every day, millions of patients and caregiver.
- 06/06/2024
|
7 Deeply Undervalued Stocks to Buy Now or Regret Later
- If you screen some of the top stocks on the market today, you'll realize they were among some of the most deeply undervalued stocks at some point in the past decade. Most people looking at their charts now wish they were one of the contrarians who bought these stocks when they were trading at bargain-basement prices.
- 06/05/2024
|
5 Relatively Secure And Cheap Dividend Stocks To Invest In - June 2024
- This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields about 3.5%, we present two other groups of five DGI stocks each, with the goal of moderate to high yields.
- 06/01/2024
|
New Cohort Study Data Shows Baxter's Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global innovator in kidney care and vital organ support, today announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis (HF HD). The study, “Survival of expanded hemodialysis and high-flux hemodialysis patients in Colombia: a cohort study,” was p.
- 05/29/2024
|
Reasons to Retain Baxter International (BAX) in Your Portfolio Now
- Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.
- 05/29/2024
|
Why Baxter International (BAX) is a Top Value Stock for the Long-Term
- Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 05/24/2024
|
Baxter to Present at Jefferies 2024 Global Healthcare Conference
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Jefferies 2024 Global Healthcare Conference on Wednesday, June 5, 2024. Joel Grade, Baxter's chief financial officer, is scheduled to present at 9:30 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Monday, December 2, 2024. About Baxter Every day, millions of patients and caregivers rely on Ba.
- 05/23/2024
|
Baxter Announces Mission and Logo for Proposed Kidney Care Company Vantive
- DEERFIELD, Ill.--(BUSINESS WIRE)-- #AccessKidneyCare--Baxter International Inc. (NYSE:BAX), a global medtech leader, announced today the mission and logo for its proposed kidney care and acute therapies company, to be named Vantive. The Vantive mission, Extending Lives, Expanding Possibilities, will guide and inspire the proposed company, which will focus on vital organ therapies for acute and chronic kidney diseases and beyond. This larger purpose will drive Vantive employees to passionately develop solutions tha.
- 05/15/2024
|
Baxter's (BAX) Clinolipid Gets FDA's Expanded Indication
- Baxter's (BAX) receipt of the latest expanded indication for Clinolipid is expected to meet the diverse nutritional needs of patients, ranging from preterm neonates to adults.
- 05/14/2024
|
Baxter Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, today announced U.S. FDA approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) to be used in pediatric patients, including preterm and term neonates. Clinolipid is Baxter's proprietary mixed oil lipid emulsion that is used to provide calories and essential fatty acids in parenteral (intravenous) nutrition (PN) when oral or enteral nutrition is not possible, insuf.
- 05/13/2024
|
Baxter to Present at Bank of America 2024 Health Care Conference
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Bank of America 2024 Health Care Conference on Wednesday, May 15, 2024. Joel Grade, Baxter's chief financial officer, is scheduled to present at 3:00 p.m. Pacific Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Wednesday, August 14, 2024. About Baxter Every day, millions of patients and caregivers rely on.
- 05/07/2024
|
Baxter Declares Quarterly Dividend
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock. The dividend is payable on July 1, 2024, to stockholders of record as of May 31, 2024. The indicated annual dividend rate is $1.16 per share of common stock. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagn.
- 05/07/2024
|
The Big Split: 3 Stock Spinoffs Are Coming. Should You Buy?
- “Do one thing and do it well.” Over time, companies forget that sage advice, preferring instead to build mini empires.
- 05/03/2024
|
Compared to Estimates, Baxter (BAX) Q1 Earnings: A Look at Key Metrics
- Although the revenue and EPS for Baxter (BAX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 05/02/2024
|
Baxter (BAX) Q1 Earnings Beat Estimates, '24 EPS View Raised
- Baxter (BAX) reports better-than-expected first-quarter earnings and sales. BAX's quarterly results reflect solid demand for a range of its medically essential products.
- 05/02/2024
|
Baxter International (BAX) Q1 Earnings and Revenues Surpass Estimates
- Baxter International (BAX) came out with quarterly earnings of $0.65 per share, beating the Zacks Consensus Estimate of $0.61 per share. This compares to earnings of $0.59 per share a year ago.
- 05/02/2024
|
Baxter Reports First-Quarter 2024 Results
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2024. “Baxter's results in the first quarter reflect the company's solid operational performance, fueled by the benefits being realized from our ongoing strategic transformation initiatives, including our new operating model structure, and continued strong execution across our integrated supply chain network,” said José (Joe) E. Almeida, chair, preside.
- 05/02/2024
|
Ahead of Baxter (BAX) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
- Besides Wall Street's top -and-bottom-line estimates for Baxter (BAX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
- 04/29/2024
|
Exergen Sues Baxter International to Defend Its Right to Publish Data Regarding the Accuracy of Oral Thermometers
- WATERTOWN, Mass.--(BUSINESS WIRE)--Last week Exergen Corporation filed a lawsuit against Baxter International Inc. in the United States District Court for the District of Massachusetts. As detailed in its complaint, Exergen's lawsuit is a response to an effort by Baxter to censor true statements that Exergen has made in a scientific journal about a matter of public concern, among other issues. Through its lawsuit, Exergen seeks a legal declaration that its statements are not only true, but that.
- 04/24/2024
|
My Pink Slip Picks: 3 CEOs That Need to Be Fired
- It's been a month since Boeing (NYSE: BA ) CEO Dave Calhoun announced that he would step down at the end of 2024. While his departure wasn't termed a “firing,” there is no question Calhoun's name would have been on a list, if there were one, of CEOs that need to be fired.
- 04/23/2024
|
Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO
- SAN DIEGO--(BUSINESS WIRE)--Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience. He was most recently the president and CEO of Aptinyx (NASDAQ: APTX), a clinical-stage CNS-focused biotech company. His previous experience includes senior leadership roles at Baxter International (NYSE: BAX) and The Boston Consulting Group. “We are excited.
- 04/23/2024
|
Equity Investing Is About The Way Things Are, Not The Way Things Should Be
- Rob Isbitts discusses navigating market risk and why the easy money era is over. Investors need to focus on both offense and defense in their portfolio strategy.
- 04/22/2024
|
Baxter's (BAX) New Injectables Aid Its Pharmaceutical Portfolio
- Baxter (BAX) unveils its five injectable products, which strengthen its emphasis on unique products and expand the pharmaceutical portfolio of the business in important therapeutic areas.
- 04/12/2024
|
3 Medical Device Stocks With Solid Dividend Yield: CAH & Others
- Here we discuss three medical device stocks, Cardinal Health (CAH), Baxter International (BAX) and Fresenius Medical Care (FMS), with a solid five-year dividend growth history.
- 04/11/2024
|
Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in injectables, anesthesia and drug compounding, announced the continued expansion of its Pharmaceuticals portfolio with five injectable product launches in the U.S. “These launches demonstrate Baxter's focus on differentiated products that address unmet patient needs in key therapeutic areas, including anti-infective and anti-hypotensive medications,” said Alok Sonig, executive vice president and group pres.
- 04/11/2024
|
Baxter to Host First-Quarter 2024 Financial Results Conference Call for Investors
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2024 financial results on Thursday, May 2, 2024 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I215737 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. Th.
- 04/10/2024
|
Reasons to Hold Baxter International (BAX) in Your Portfolio
- Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, raises optimism.
- 04/10/2024
|
Baxter's (BAX) Latest FDA Approval to Boost Infusion Therapy
- Baxter's (BAX) Novum IQ Infusion Platform is likely to help enhance patient safety and efficiency for clinicians following the FDA's clearance.
- 04/02/2024
|
10 Coiled Spring Blue-Chip Bargain Buys
- The market is near record highs and NVDA is up 11 straight weeks. Yet, blue-chip coiled spring bargains are still bountiful. VFLO is the best deep value strategy ETF I've found. A great combo of deep value, quality, and growth. It's beating the S&P, value, and even the Nasdaq since inception. Combining ETFs with individual stocks is a great way to potentially achieve superior returns and yield than ETFs can achieve.
- 03/29/2024
|
Baxter to Present at Raymond James 45th Annual Institutional Investors Conference
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Raymond James 45th Annual Institutional Investors Conference on Monday, March 4, 2024. Joel Grade, Baxter's chief financial officer, is scheduled to present at 4:00 p.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Friday, May 31, 2024. About Baxter Every day, millions of patients and caregivers.
- 02/29/2024
|
Baxter International Inc. Is A Buy (Technical Analysis)
- Baxter International Inc. is a buy according to the analysis of price action, momentum, volume, and relative strength.
- 02/26/2024
|
Baxter's (BAX) Q4 Earnings Top, Sales Rise on Strong Demand
- Baxter (BAX) reports better-than-expected fourth-quarter earnings and sales. BAX's fourth-quarter and full-year results reflect solid demand for a range of its medically essential products.
- 02/08/2024
|
Baxter (BAX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
- The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 02/08/2024
|
Baxter International (BAX) Tops Q4 Earnings and Revenue Estimates
- Baxter International (BAX) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.88 per share a year ago.
- 02/08/2024
|
Medical device maker Baxter beats sales and profit estimates on strong demand
- Baxter International beat Wall Street expectations for fourth-quarter sales and profit on Thursday on strong demand for its medical devices and improvements in the supply chain environment.
- 02/08/2024
|
MoneyShow's Best Investment Ideas For 2024: Part 2
- MoneyShow presents top investment ideas for 2024 from their contributors. This year's edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth stocks, as well as ETF recommendations that target commodities, cryptocurrencies, and fixed income.
- 01/26/2024
|
Baxter to Host Fourth-Quarter 2023 Financial Results Conference Call for Investors
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2023 financial results on Thursday, February 8, 2024 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/etCeELhb to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.
- 01/04/2024
|
Reasons to Retain Baxter International (BAX) in Your Portfolio
- Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.
- 12/14/2023
|
Baxter to Present at 42nd Annual J.P. Morgan Healthcare Conference
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. José (Joe) E. Almeida, Baxter's chairman, president and chief executive officer, is scheduled to present at 10:30 a.m. Pacific Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Friday, July 5, 2024. About Baxter Every day, millions of.
- 12/13/2023
|
Strategist: Buy Baxter stock, skip Eli Lilly stock
- Novo Nordisk (NVO) was named Yahoo Finance's Company of the Year thanks to the success of its diabetes and weight loss drugs, Ozempic and Wegovy. But there are other ways you can play the GLP-1 hype.
- 12/12/2023
|
Baxter International: A Cheap Big Pharma Stock With Improving Earnings And +3% Dividend Yield
- Baxter International stock rated Buy, agreeing with Wall Street consensus. Tailwinds coming from positive revenue, earnings, and equity growth. Cheap share price below moving average combined with +3% dividend yield, for a company that returned to profitability.
- 12/12/2023
|
Baxter (BAX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
- The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 11/03/2023
|
Baxter International beats Q3 profit estimates on strong demand for medical devices
- Baxter International on Thursday beat Wall Street expectations for third-quarter revenue and profit, as a recovery in surgical procedure volumes after the pandemic helped drive the demand for its medical devices higher.
- 11/02/2023
|
BAX vs. SYK: Which Stock Is the Better Value Option?
- Investors looking for stocks in the Medical - Products sector might want to consider either Baxter International (BAX) or Stryker (SYK). But which of these two stocks is more attractive to value investors?
- 10/30/2023
|
Baxter (BAX) to Report Q3 Earnings: Is a Beat in Store?
- Baxter's (BAX) third-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.
- 10/30/2023
|
The Value Deepens for Medtech Stocks: Reversal Imminent
- Results from Johnson & Johnson NYSE: JNJ and Abbott Laboratories NYSE: ABT foreshadow good news for MedTech investors. Both companies outperformed on the top and bottom lines, driven by broad strength in their MedTech units.
- 10/23/2023
|
Baxter's (BAX) New Launch to Enable Earlier Treatment of Eye
- Baxter's (BAX) latest offering is likely to enable a more digitally-connected primary care examination and support faster diagnosis for earlier treatment of eye conditions.
- 10/18/2023
|
What other industries could weight loss drugs disrupt?
- Jared Holz, Mizuho health care sector strategist, joins the ‘Fast Money' traders to discuss Novo Nordisj's kidney trial outcomes and the impact of weight loss drugs on the health care sector.
- 10/11/2023
|
Why Investors Punished Baxter International Stock Today
- A drug made by a rival tested well in a clinical trial for kidney disease. That treatment is currently a very hot product, but for different indications.
- 10/11/2023
|
The 3 Widest Competitive Moats on Wall Street
- Competitive moats symbolize a company's sustainable advantage, protecting it from competitors and external threats. Three standout examples illustrate this principle vividly.
- 10/11/2023
|
Baxter to Host Third-Quarter 2023 Financial Results Conference Call for Investors
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2023 financial results on Thursday, November 2, 2023 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/etCeELhb to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.c.
- 09/19/2023
|
Reasons to Retain Baxter International (BAX) in Your Portfolio
- Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.
- 09/12/2023
|
A Significant Reversal is in Sight for These 5 Med Tech Companies
- Med tech has been on the skids for no fault of its own. It's not the industry's fault that price action was driven to a frothy bubble by COVID-inspired trading outlooks or that the market has normalized.
- 08/30/2023
|
Baxter to Present at Morgan Stanley 21st Annual Global Healthcare Conference
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023. José (Joe) E. Almeida, Baxter's chairman, president and chief executive officer, is scheduled to present at 9:30 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through March 13, 2024. About Baxter Every day, mil.
- 08/29/2023
|
Will Baxter Stock Recover To Its Pre-Inflation Shock Highs?
- Although there has been a steady decline in the inflation rate in response to the Fed's aggressive rate hike plan, investors still have concerns about a potential rece
- 08/28/2023
|
Baxter to Present at 2023 Wells Fargo Healthcare Conference
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7, 2023. José (Joe) E. Almeida, Baxter's chairman, president and chief executive officer is scheduled to present at 8:45 a.m. EST. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through March 5, 2024. About Baxter Every day, millions of patients and caregive.
- 08/22/2023
|
Dividend Challengers Review: Baxter International
- Baxter International has seen 7 consecutive years of dividend growth, but has not raised its dividend this year. The company's financials show slow revenue growth and a dramatic drop in earnings. Baxter's stock price has declined significantly over the past five years, making it a less attractive investment option compared to peers.
- 08/14/2023
|
Baxter (BAX) Beats on Q2 Earnings, Revises 2023 EPS Guidance
- Baxter's (BAX) second-quarter 2023 results reflect sustained demand for its medically essential products amid a stabilizing macroeconomic climate and healthcare marketplace.
- 07/27/2023
|
Baxter (BAX) to Post Q2 Earnings: What's in the Offing?
- Baxter's (BAX) second-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.
- 07/21/2023
|
Earnings Preview: Baxter International (BAX) Q2 Earnings Expected to Decline
- Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/20/2023
|
3 Dividend Growth Stocks Raising Dividends
- Income investors tend to focus on stocks with high dividend yields. This is understandable, as investors such as retirees need current income.
- 07/07/2023
|
Baxter's (BAX) New Launch to Support Complex Critical Care Needs
- Baxter's (BAX) Progressa+ bed for the ICU is expected to enhance workflow and reduce strain on nursing resources.
- 06/30/2023
|
Dividend Champion, Contender, And Challenger Highlights: Week Of June 25
- A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
- 06/25/2023
|
Baxter to Host Second-Quarter 2023 Financial Results Conference Call for Investors
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its second-quarter 2023 financial results on Thursday, July 27, 2023 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/XvgzXupv to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com.
- 06/13/2023
|
Baxter International: Hillrom Acquisition Could Be A Tailwind For FCF
- Baxter International Inc plans to divest its BioPharma Solutions business for $4.25 billion, aiming to pay down its long-term debt and create room for further growth. The company's robust margins and cash flows, along with a diverse product portfolio, make it an attractive option for a dividend-oriented portfolio. Despite the risks associated with the large amount of debt on the balance sheet, Baxter International Inc is rated as a buy due to its stable dividend yield and potential for share appreciation.
- 06/12/2023
|
Baxter to Present at Jefferies Healthcare Conference
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023. José (Joe) Almeida, Baxter's chairman, president and chief executive officer, is scheduled to present at 10:00 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Wednesday, September 6, 2023. About Baxter Every day, millions of patients a.
- 05/24/2023
|
Baxter to sell its BioPharma business for $4.25 billion to Advent International, Warburg Pincus as part of ‘transformation journey'
- Shares of Baxter International Inc. BAX rose 1.2% in premarket trading Monday, after the health care products company announced an agreement to divest its BioPharma Solutions business to private-equity investor Advent International and Warburg Pincus. Under terms of the agreement, Baxter will receive $4.25 billion in cash, which the company plans to use to pay down debt.
- 05/08/2023
|
BAX vs. SYK: Which Stock Should Value Investors Buy Now?
- Investors interested in stocks from the Medical - Products sector have probably already heard of Baxter International (BAX) and Stryker (SYK). But which of these two stocks is more attractive to value investors?
- 05/02/2023
|
Baxter International Inc. (BAX) Q1 2023 Earnings Call Transcript
- Baxter International Inc. (BAX) Q1 2023 Earnings Call Transcript.
- 04/27/2023
|
Are Investors Undervaluing Baxter International (BAX) Right Now?
- Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 04/25/2023
|
Baxter (BAX) to Post Q1 Earnings: What's in the Offing?
- Baxter's (BAX) first-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.
- 04/20/2023
|
Baxter to Present at BofA Securities 2023 Health Care Conference
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the BofA Securities 2023 Health Care Conference on Tuesday, May 9, 2023. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 1:00 p.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through November 5, 2023.
- 04/19/2023
|
3 Reasons To Consider A Nibble On Baxter
- H1-23 is likely to be challenging, but drastic adjustments have already been made to forward estimates, with valuations now looking attractive. FCF could double in FY23 as working capital dynamics pick up, and the potential sale of BPS could also help reduce debt levels.
- 04/11/2023
|
Baxter's (BAX) New Premix Drug Now Available in the U.S.
- Baxter's (BAX) latest frozen premix formulation is expected to support patient safety, simplify medication preparation and boost operational efficiencies.
- 04/10/2023
|
Baxter to Host First-Quarter 2023 Financial Results Conference Call for Investors
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2023 financial results on Thursday, April 27, 2023 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/WhpPxesO to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.
- 04/06/2023
|
Dividend Champion, Contender, And Challenger Highlights: Week Of March 26
- A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.
- 03/25/2023
|
Exclusive: Thermo Fisher, Celltrion vie for Baxter's biopharma unit -sources
- U.S. scientific instruments maker Thermo Fisher Scientific Inc and South Korea's Celltrion Inc are among
- 03/20/2023
|
Is It Time to Buy the S&P 500's 4 Worst-Performing Stocks of 2023?
- Lumen's slowing growth, high debt, and dividend cut spooked the bulls. Moderna and Pfizer both face tough post-pandemic slowdowns.
- 03/05/2023
|
Dividend Champion, Contender, And Challenger Highlights: Week Of February 19
- A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.
- 02/19/2023
|
Why Baxter International Stock Sank by 12% This Week
- Macroeconomic woes were taking a toll on the medical tech company.
- 02/10/2023
|
Baxter International Inc. (BAX) Q4 2022 Earnings Call Transcript
- Baxter International Inc. (NYSE:BAX ) Q4 2022 Earnings Conference Call February 9, 2023 8:30 AM ET Company Participants Clare Trachtman - Vice President of Investor Relations José Almeida - Chairman, President & Chief Executive Officer James Saccaro - Executive Vice President & Chief Financial Officer Conference Call Participants Pito Chickering - Deutsche Bank Robbie Marcus - JPMorgan Vijay Kumar - Evercore ISI Matthew Mishan - KeyBanc Matt Miksic - Barclays Lawrence Biegelsen - Wells Fargo Operator Good morning ladies and gentlemen and welcome to Baxter International's Fourth Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded by Baxter and is copyrighted material.
- 02/09/2023
|
Baxter (BAX) Q4 Earnings Miss Estimates, FY23 Outlook Weak
- Baxter's (BAX) fourth-quarter results reflect impact of additional sales from the legacy Hilrom's business acquired in 2021. Ongoing macroeconomic challenges hurt earnings significantly.
- 02/09/2023
|
Baxter International (BAX) Lags Q4 Earnings Estimates
- Baxter (BAX) delivered earnings and revenue surprises of -6.38% and 3.05%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/09/2023
|
5 Best and Worst Performing Health Care Stocks in December 2022
- Despite inflation making it hard for the healthcare industry to manage its operating costs, there are a few positives that make this sector attractive to investors.
- 01/23/2023
|
I'll Avoid These Sectors In 2023
- I wrote an article about which sectors I intend to focus on for this year, with a number of example picks for each sector. In this article, it's the opposite. I will show you what sectors I will try to avoid, given volatility or negative potential for these sectors.
- 01/15/2023
|
Baxter (BAX) Plans to Form Standalone Kidney Care Company
- Baxter (BAX) plans several strategic actions, including spin-off of Renal Care and Acute Therapies global business units into an independent, publicly traded company to simplify its operating model.
- 01/09/2023
|
Baxter - Steak at Hamburger Prices
- Baxter International Inc. ( BAX , Financial) is a health care company that offers a wide range of products and services such as dialysis treatments, IV solutions, infusion systems, parenteral nutrition therapies, inhaled anesthetics, generic injectable drugs and surgical products. As of its most recent annual report on Dec. 31, 2021, the company had manufacturing operations in more than 20 countries and sold its products in over 100 countries.
- 01/06/2023
|
Baxter stock drops on plan to restructure and spin off kidney care unit
- Baxter International Inc. said Friday it plans to embark on a tax-free spin off to shareholders of its Renal Care and Acute Therapies unit into a public company within the next 12-18 months.
- 01/06/2023
|
Why Baxter Is One Of My #1 2023 Bets For Healthcare/Medtech
- In this article, I'll be taking a look at a recent investment favorite of mine that I have been slowly allocating to in line with the declines. I'm talking about Baxter International, a globally diversified Healthcare equipment business. It's not the highest yielder, but the upside to the business is potentially massive.
- 01/02/2023
|
100 Best Stocks Of 2022: Oil Stocks And Medicals Shine
- Medical and energy companies, including oil stocks, lead the list of the 100 best stocks in 2022. The post 100 Best Stocks Of 2022: Oil Stocks And Medicals Shine appeared first on Investor's Business Daily.
- 12/30/2022
|
Will Baxter Stock Rebound After A 9% Fall In A Month?
- The broader markets have been falling of late on positive economic data, which implies that the Fed may have to continue to increase interest rates, likely resulting in a recession in 2023.
- 12/27/2022
|
Is the Options Market Predicting a Spike in Baxter International (BAX) Stock?
- Investors need to pay close attention to Baxter International (BAX) stock based on the movements in the options market lately.
- 12/15/2022
|
2 Dividend Stocks That Have Raised Their Payouts by 80% in 5 Years
- Can these stocks continue hiking their dividend payments?
- 12/07/2022
|
Baxter to Present at the 5th Annual Evercore ISI HealthCONx Conference
- DEERFIELD, Ill.--( BUSINESS WIRE )--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 5th Annual Evercore ISI HealthCONx Conference on Thursday, December 1, 2022. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 1:00 p.m. Eastern Time.
- 11/16/2022
|
Baxter International Inc. (BAX) Q3 2022 Earnings Call Transcript
- Start Time: 08:30 January 1, 0000 9:32 AM ET Baxter International Inc. (NYSE:BAX ) Q3 2022 Earnings Conference Call October 27, 2022, 08:30 AM ET Company Participants José Almeida - Chairman, President and CEO James Saccaro - EVP and CFO Clare Trachtman - VP, IR Conference Call Participants Travis Steed - Bank of America Securities Robbie Marcus - JPMorgan Rick Wise - Stifel Pito Chickering - Deutsche Bank Joanne Wuensch - Citigroup Joshua Jennings - Cowen and Company Operator Good morning, ladies and gentlemen, and welcome to Baxter International's Third Quarter 2022 Earnings Conference Call. Your lines will remain in a listen-only mode until the question-and-answer segment of today's call.
- 10/27/2022
|
Baxter International: Despite Weakening On The Bottom Line, Shares Look Attractive
- Baxter International has had a rough year or so, with shares declining far more than the market has. Some of this was justified by the company's high share price and weakening fundamentals.
- 10/23/2022
|
Baxter (BAX) to Report Q3 Earnings: Is a Beat in the Cards?
- Baxter's (BAX) third-quarter results are likely to reflect growth in its Medication Delivery and Advanced Surgery businesses. Hillrom's products are likely to have boosted sales.
- 10/20/2022
|
3 Reasons to Retain Baxter (BAX) Stock in Your Portfolio
- Investors remain optimistic about Baxter (BAX) due to its strong product portfolio.
- 10/12/2022
|
These Are The Top 10 Holdings Of Larry Robbins
- Larry Robbins is the founder and CEO of Glenview Capital Management, which is a New York-based hedge fund.
- 10/11/2022
|
Should You Buy Baxter Stock Under $60?
- Baxter stock (NYSE: BAX) has seen a 32% fall this year, underperforming the broader S&P500 index, down 17%.
- 09/15/2022
|
Baxter to Host Third-Quarter 2022 Financial Results Conference Call for Investors
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2022 financial results on Thursday, October 27, 2022 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/EmxweYhQ to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.c
- 09/07/2022
|
Two-Minute Drill: FedEx, Verizon & Baxter
- Burns McKinney, NFJ Investment, joins ‘Closing Bell: Overtime' to give his take on FedEx, Verizon and Baxter.
- 08/31/2022
|
Baxter to Present at the 2022 Wells Fargo Healthcare Conference
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 10:25 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through February 23, 2023. About Baxter Every day, millions of patients and caregivers rely on Baxter'
- 08/30/2022
|
Baxter to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 10:35 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through March 13, 2023. About Baxter Every day, millions of patients and caregivers
- 08/25/2022
|
Baxter's Shares Are Starting To Look Cheap
- Baxter boasts a broad portfolio of medically necessary products and therapies, and its brand strength is a key advantage. The company's products can be found in just about any healthcare facility from hospitals to nursing homes and beyond in over 100 countries.
- 08/11/2022
|
Baxter (BAX) Q2 Earnings Miss Estimates, Hilrom Adds $715 M
- Baxter's (BAX) second-quarter results reflect the robust performance of the Medication Delivery business unit and Hilrom's businesses.
- 07/28/2022
|
Baxter International Inc. (BAX) CEO José Almeida on Q2 2022 Results - Earnings Call Transcript
- Baxter International Inc. (NYSE:BAX ) Q2 2022 Results Earnings Conference Call July 28, 2022 8:30 AM ET Company Participants Clare Trachtman - Vice President, Investor Relations José Almeida - Chairman, President and Chief Executive Officer James Saccaro - Executive Vice President and Chief Financial Officer Conference Call Participants Robbie Marcus – J.P. Morgan Vijay Kumar - Evercore ISI Pito Chickering - Deutsche Bank Travis Steed - Bank of America Securities Joanne Wuensch - Citigroup Larry Biegelsen - Wells Fargo Joshua Jennings - Cowen and Company Operator Good morning, ladies and gentlemen, and welcome to Baxter International's Second Quarter 2022 Earnings Conference Call.
- 07/28/2022
|
Baxter International (BAX) Misses Q2 Earnings and Revenue Estimates
- Baxter (BAX) delivered earnings and revenue surprises of -1.14% and 3.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 07/28/2022
|
A Debt-Free and Fairly Valued Medical Devices Company
- LeMaitre Vascular Inc. ( LMAT , Financial) has been on a roll—it has generated robust financial results and metrics that produced a high GF Score. But the share price has been in a slump.
- 07/20/2022
|
Daily Dividend Report: Cummins, Marsh McLennan, Baxter International, Realty Income, Phillips 66
- Daily Dividend Report: Cummins, Marsh McLennan, Baxter International, Realty Income, Phillips 66
- 07/13/2022
|
3 Reasons to Retain Baxter (BAX) Stock in Your Portfolio
- Investors remain optimistic about Baxter (BAX) due to its strong product portfolio.
- 07/06/2022
|
Baxter to Host Second-Quarter 2022 Financial Results Conference Call for Investors
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its second-quarter 2022 financial results on Thursday, July 28, 2022 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/EmxweYhQ to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com
- 06/08/2022
|
Here's Why You Should Retain Baxter (BAX) Stock For Now
- Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio and regulatory clearances.
- 06/06/2022
|
Baxter to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022. José (Joe) Almeida, Baxter's chairman and chief executive officer, is scheduled to present at 10:40 a.m. Pacific Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through June 13, 2023. About Baxter Every day, millions of patients and
- 06/02/2022
|
14 Upcoming Dividend Increases Including A Soon To Be King
- All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 12.4% and a median increase of 10.3%. I've tracked 282 increases in 2022, 211 increases in Q1 2022, and 71 in Q2.
- 05/26/2022
|
Baxter Highlights Business Strategies and Innovation at 2022 Investor Conference
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will showcase its ongoing trajectory of transformation and growth at its 2022 Investor Conference, being held today in Glenview, Ill. The company's executive leadership team will highlight Baxter's strategy to continue creating compelling value for patients, clinicians and investors through leading-edge innovation, market expansion, operational efficiency and other vital growth levers. This is Baxte
- 05/25/2022
|
Baxter to Host 2022 Investor Conference
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host an investor conference on Wednesday, May 25, 2022 in Glenview, Ill. Chairman and CEO Joe Almeida and other members of Baxter's management team will provide a closer look at the company's growth strategy, innovation pipeline and longer term financial outlook. The investor conference will feature an innovation hall displaying product and therapy advancements from Baxter's pipeline beginning
- 05/10/2022
|
7 Defensive Dividend Healthcare Stocks to Buy Now
- As market conditions remain rocky, adding high-quality healthcare stocks to your portfolio may be a great way to play defense. The post 7 Defensive Dividend Healthcare Stocks to Buy Now appeared first on InvestorPlace.
- 05/06/2022
|
Baxter: Some Real 'Buy' Appeal
- I've been on a crusade for the past 2 weeks to highlight investable dividend-paying quality business as we're experiencing a market drop. My work takes me now to revisit the company Baxter International, a quality business in the medical supply field. I wrote about the company several months ago.
- 05/03/2022
|
Red-Hot Energy Companies Among 5 ‘Strong Buy' Stocks With Expected Dividend Hikes This Week
- After years of a low interest rate environment, many investors have turned to equities, not only for the growth potential but also for solid and dependable dividends that help to provide an income stream.
- 05/02/2022
|
Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates
- Baxter's (BAX) first-quarter results reflect robust performance across four of its business units.
- 04/28/2022
|
Baxter International Inc. (BAX) CEO Joe Almeida on Q1 2022 Results - Earnings Call Transcript
- Baxter International Inc. (NYSE:BAX ) Q1 2022 Results Conference Call April 28, 2022 8:30 AM ET Company Participants Clare Trachtman - VP, IR Joe Almeida - Chairman, CEO Giuseppe Accogli - COO Jay Saccaro - CFO Conference Call Participants Drew Ranieri - Morgan Stanley Danielle Antalffy - SVB Leerink Joanne Wuensch - Citi Larry Biegelsen - Wells Fargo Matt Miksic - Credit Suisse Pito Chickering - Deutsche Bank Robbie Marcus - JP Morgan Travis Steed - Bank of America Vijay Kumar - Evercore ISI Operator Good morning, ladies and gentlemen, and welcome to Baxter International's First Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded by Baxter and is copyrighted material.
- 04/28/2022
|
Baxter International (BAX) Surpasses Q1 Earnings and Revenue Estimates
- Baxter (BAX) delivered earnings and revenue surprises of 16.25% and 1.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 04/28/2022
|
Baxter International (BAX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
- Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/21/2022
|
Here's Why You Should Retain Baxter (BAX) Stock For Now
- Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio and regulatory clearances.
- 04/21/2022
|
Baxter (BAX) to Report Q1 Earnings: What's in the Offing?
- Baxter's (BAX) first-quarter results are likely to reflect growth in its Acute Therapies business.
- 04/21/2022
|
Baxter's (BAX) ST Set Receives FDA Nod, to Boost Patient Outcome
- Baxter's (BAX) ST Set is expected to improve treatments in an acute care environment.
- 04/06/2022
|
Baxter to Host First-Quarter 2022 Financial Results Conference Call for Investors
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2022 financial results on Thursday, April 28, 2022 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/EmxweYhQ to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com
- 03/23/2022
|
Here's Why You Should Retain Baxter (BAX) Stock For Now
- Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.
- 03/16/2022
|
Baxter (BAX) to Enhance Its Portfolio With Latest Partnership
- Baxter's (BAX) latest strategic partnership with Digital Diagnostics is expected to expand its connected care diagnostics portfolio.
- 03/14/2022
|
IHI: A Standout Performer With Equally Strong Future Growth Prospects
- IHI: A Standout Performer With Equally Strong Future Growth Prospects
- 03/05/2022
|
Baxter to Present at the Barclays Global Healthcare Conference
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Barclays Global Healthcare Conference on Thursday, March 17, 2022. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 8:00 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through September 13, 2022. About Baxter Every day, millions of patients and caregivers rely on Baxter's lea
- 03/01/2022
|
Baxter: A Potential Premium Upside Of 15%
- I wrote about Baxter a few months back, considering the company a conservative "BUY" based on good fundamentals and M&A. While the company hasn't outperformed, it hasn't dropped either. So far, realizing its growth potential hasn't happened.
- 02/21/2022
|
Riding The Stock Waves: Update On The Medical Devices Sector
- Riding The Stock Waves: Update On The Medical Devices Sector
- 02/21/2022
|
Baxter (BAX) Stock: Why Its Trending Today
- The Baxter (NYSE: BAX) stock is trending today. This is why.
- 02/18/2022
|
Baxter International's (BAX) CEO Joe Almeida on Q4 2021 Results - Earnings Call Transcript
- Baxter International's (BAX) CEO Joe Almeida on Q4 2021 Results - Earnings Call Transcript
- 02/17/2022
|
Baxter (BAX) Q4 Earnings and Revenues Surpass Estimates
- Baxter's (BAX) fourth-quarter results reflect robust performance across six of its business units.
- 02/17/2022
|
Baxter Clocks Better-Than-Expected Q4 Earnings, But FY22 Guidance Trail Street View
- Baxter International Inc (NYSE: BAX) has posted Q4 revenue of $3.5 billion, beating the consensus of $3.35 billion, up 10% on a reported basis, 12% on a constant currency basis, and 4% on an operational basis. Adjusted EPS of $1.04 increased 30%, marginally ahead of the consensus of $1.03.
- 02/17/2022
|
Baxter International (BAX) Tops Q4 Earnings and Revenue Estimates
- Baxter (BAX) delivered earnings and revenue surprises of 0.97% and 4.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/17/2022
|
BAX vs. SYK: Which Stock Should Value Investors Buy Now?
- BAX vs. SYK: Which Stock Is the Better Value Option?
- 02/15/2022
|
Baxter (BAX) to Report Q4 Earnings: What's in the Offing?
- Baxter's (BAX) fourth-quarter results are likely to reflect growth in its Acute Therapies business.
- 02/14/2022
|
10 Health Care Stocks Warren Buffett Owns That Offer Safety and Dependable Dividends
- If any investor has stood the test of time, it is Warren Buffett, and with good reason.
- 02/14/2022
|
Baxter to Present at Citi's 2022 Virtual Healthcare Conference
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at Citi's 2022 Virtual Healthcare Conference on Wednesday, February 23, 2022. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 1:15 p.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through February 22, 2023. About Baxter Every day, millions of patients and caregivers rely on Baxter's
- 02/10/2022
|
Baxter (BAX) Hits 52-Week High: What's Aiding the Stock?
- Investors are optimistic about Baxter's (BAX) strong product portfolio.
- 02/10/2022
|
Why Baxter (BAX) Could Beat Earnings Estimates Again
- Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 02/07/2022
|
3 Medical Products Stocks Poised to Beat This Earnings Season
- The Medical Products companies' Q4 results are likely to reflect base business recovery. Let's see how BAX, HSIC, and XRAY are poised ahead of their earnings releases.
- 02/07/2022
|
Is Baxter International (BAX) Outperforming Other Medical Stocks This Year?
- Here is how Baxter International (BAX) and Gamida Cell (GMDA) have performed compared to their sector so far this year.
- 02/07/2022
|
10 Dividend Growth Stocks For January 2022
- I rank a selection of dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration. To pick candidates, I use different screens every month that focus on various aspects of dividend growth investing such as valuation, yield, and growth.
- 01/30/2022
|
New Strong Buy Stocks for January 18th
- KBH, BAX, F, EGO, and AXS have been added to the Zacks Rank #1 (Strong Buy) List on January 18, 2022.
- 01/18/2022
|
Best Income Stocks to Buy for January 18th
- BAX, F, and WBS made it to the Zacks Rank #1 (Strong Buy) income stocks list on January 18, 2022
- 01/18/2022
|
Best Momentum Stocks to Buy for January 18th
- BAX, F, and EGO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 18, 2022
- 01/18/2022
|
5 Low-Beta High-Yielding Stocks to Buy in a Capricious Market
- We have narrowed our search to five large-cap low-beta stocks with a solid dividend yield. These are: PFE, BAX, IBKR, PSA and CUBE.
- 01/18/2022
|
New Strong Buy Stocks for January 17th
- AXS, BAX, F, UNFI, and BRDG have been added to the Zacks Rank #1 (Strong Buy) List on January 17, 2022.
- 01/17/2022
|
Here's Why You Should Retain Baxter (BAX) Stock For Now
- Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.
- 01/07/2022
|
Baxter to Host Fourth-Quarter 2021 Financial Results Conference Call for Investors
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2021 financial results on Thursday, February 17, 2022 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/3168996 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at
- 01/06/2022
|
4 Stocks to Watch Out For as MedTech Rides on Buyout Frenzy
- Here are some MedTech stocks - Quidel (QDEL), Thermo Fisher (TMO), Baxter (BAX) and BD (BDX) - that have been quite active in the acquisition front and therefore worth investor attention.
- 01/06/2022
|
Options Income Series: Earn High Income Safely And Consistently - December 2021
- We explain why selling the cash-covered puts and covered calls is a safer choice and earns a high income. We will discuss how to formulate an options income strategy that's sustainable and repeatable.
- 12/25/2021
|
Baxter International Stock (BAX): Why The Price Increased
- The stock price of Baxter International Inc. (NYSE:BAX) increased by 2.89% in the most recent trading session. This is why it happened.
- 12/14/2021
|
Here's Why You Should Retain Baxter (BAX) Stock For Now
- Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.
- 12/07/2021
|
4 MedTech Dividend Stocks in Focus on Amid Omicron Variant Panic
- Abbott Laboratories (ABT), West Pharmaceuticals Services (WST), Baxter International (BAX) and Chemed Corporation (CHE) are high-yield dividend stocks with sustainable business models.
- 12/02/2021
|
Larry Robbins' Top 5 Trades of the 3rd Quarter
- Glenview Capital Management, the firm founded by Larry Robbins (Trades, Portfolio), disclosed in November that its top five trades during the third quarter included a new holding in Willis Towers Watson PLC ( WLTW , Financial), additions to its holdings in Uber Technologies Inc. ( UBER , Financial) and Baxter International Inc. ( BAX , Financial), the closure of its stake in Walgreens Boots Alliance Inc. ( WBA , Financial) and a reduction to its holding in Tenet Healthcare Corp. ( THC , Financial).
- 11/29/2021
|
Baxter's (BAX) $100M Investment to Strengthen Global Presence
- Baxter's (BAX) strategic investment to help expand the manufacturing footprint of BPS and ensure improvement in products.
- 11/16/2021
|
Baxter Shares Fall Despite Better-Than-Expected Q3 Earnings, FY21 EPS Outlook Boost
- Baxter International Inc (NYSE: BAX) posted Q3 revenue of $3.23 billion, in line with the consensus, up 9% on a reported basis, 7% on a constant currency basis, and 6% on an operational basis. Adjusted EPS of $1.02 increased 23% and surpassed the estimate of $0.94.
- 10/28/2021
|
Baxter (BAX) Q3 Earnings and Revenues Surpass Estimates
- Baxter's (BAX) third-quarter results reflect robust performance across all its business units.
- 10/28/2021
|
Baxter International (BAX) Q3 Earnings and Revenues Beat Estimates
- Baxter (BAX) delivered earnings and revenue surprises of 8.51% and 0.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 10/28/2021
|
Baxter (BAX) to Report Q3 Earnings: What's in the Offing?
- Baxter's (BAX) third-quarter results are likely to reflect growth in its Acute Therapies business.
- 10/22/2021
|
Baxter International (BAX) Earnings Expected to Grow: Should You Buy?
- Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/21/2021
|
Baxter to Present at Credit Suisse 30th Annual Virtual Healthcare Conference
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the Credit Suisse 30th Annual Virtual Healthcare Conference on Monday, November 8, 2021. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 8:50 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through November 7, 2022. About Baxter Every day, millions of patients a
- 10/13/2021
|
Should You Buy Baxter Stock Around $80?
- We believe that Baxter stock is a good buying opportunity at the present time. BAX stock trades near $81 currently and it is, in fact, down 13% from its pre-Covid high of $93 in February 2020 – just before the coronavirus pandemic hit the world.
- 10/06/2021
|
MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on
- MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.
- 09/30/2021
|
Baxter to Host Third-Quarter 2021 Financial Results Conference Call for Investors
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its third-quarter 2021 financial results on Thursday, October 28, 2021 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/3534264 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxt
- 09/27/2021
|
Baxter's (BAX) Premix Norepinephrine Now Available in U.S.
- Baxter's (BAX) norepinephrine can improve speed, efficiency and safety of treatment during critical care situations in hospital settings, and minimize compounding errors or touch contamination risks.
- 09/27/2021
|
14 High-Yield Blue Chips For A Rich Retirement
- 14 High-Yield Blue Chips For A Rich Retirement
- 09/14/2021
|
Hill-Rom Stock Rises After Baxter's Revised Bid
- Last month we discussed that the stock price of Hill-Rom Holdings, best known for its hospital beds and patient mobility solutions, will likely see further gains if Baxter were to revise its acquisition bid. Baxter has now revised its offer from $144 per share to $156 per share for Hill-Rom
- 09/13/2021
|
What's Next For Baxter Stock After An 11% Rise In A Month?
- The stock price of Baxter International, a medical supplies company, has seen a rise of around 11% over the last twenty-one trading days, and it is up just 1% over the last twelve-month period. The rally in BAX stock over the recent past has been propelled by Hill-Rom accepting Baxter's acquisition.
- 09/08/2021
|
HILL-ROM HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Hill-Rom Holdings, Inc. - HRC
- NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Hill-Rom Holdings, Inc. (NYSE: HRC) to Baxter International Inc. (NYSE: BAX). Under the terms of the proposed transaction, shareholders of Hill-Rom will receive only $156.00 in cash for each share of Hill-Rom that they own. KSF is seeking to determine whether this consideration and the process that led to it a
- 09/07/2021
|
SHAREHOLDER ALERT: WeissLaw LLP Investigates Hill-Rom Holdings, Inc.
- NEW YORK, Sept. 3, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Hill-Rom Holdings, Inc. ("Hill-Rom" or the "Company") (NYSE: HRC) in connection with the proposed acquisition of the Company by Baxter International Inc.("Baxter") (NYSE: BAX).
- 09/03/2021
|
Baxter International Inc. (BAX) CEO Joe Almeida on Hillrom Acquisition - Conference Call Transcript
- Baxter International Inc. (BAX) CEO Joe Almeida on Hillrom Acquisition - Conference Call Transcript
- 09/02/2021
|
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Hill-Rom Holdings, Inc.
- NEW YORK, Sept. 2, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Hill-Rom Holdings, Inc. (NYSE: HRC) and its board of directors concerning the proposed acquisition of the company by Baxter International Inc. (NYSE: BAX).
- 09/02/2021
|
7 Healthcare Stocks to Buy Before $3.5 Trillion Floods In
- Covid-19 showed us how rapid advances in medicine and technology could create significant growth opportunities for healthcare stocks. The post 7 Healthcare Stocks to Buy Before $3.5 Trillion Floods In appeared first on InvestorPlace.
- 09/02/2021
|
Baxter stock price forecast amid Hill-Rom acquisition rumours
- The Baxter (NYSE: BAX) stock price will be in the spotlight on Monday as rumours of its Hill-Rom acquisition resurfaced. The stock closed at $73.97 on Friday, which was about 17% below the highest point this year.
- 08/29/2021
|
The Baxter International Foundation and UNICEF USA Announce Partnership to Improve Water Security in Colombia
- DEERFIELD, Ill., & NEW YORK--(BUSINESS WIRE)--The Baxter International Foundation, the philanthropic arm of Baxter International Inc. (NYSE:BAX), and UNICEF USA today announced a partnership to improve access to safe water in La Guajira, Colombia, one of the country's most water-challenged regions. A $1.5 million grant from the Foundation is fueling the three-year initiative aimed at ensuring thousands of children, adolescents, families and communities benefit from basic water, sanitation and h
- 08/18/2021
|
What's Next For Baxter Stock After A 4% Fall Last Week?
- The stock price of medical supplies company Baxter has seen a fall of 4% over the last five trading days, while it is also down over 7% in the last year. The recent fall came after the company announced its Q2 results and reports of it planning to acquire another medical devices company - Hill-Rom.
- 08/04/2021
|
Two traders pick two underperforming stocks to buy now
- On Monday, in a recent interview on CNBC's “Trading Nation,” Chad Morganlander and Ari Wald said that the stocks in the energy and the travel sector did not perform that well due to the spike in the delta variant of the coronavirus. According to them, some of the stocks in the respective sectors were among […] The post Two traders pick two underperforming stocks to buy now appeared first on Invezz.
- 08/03/2021
|
Baxter International Inc. (BAX) CEO Joe Almeida on Q2 2021 Results - Earnings Call Transcript
- Baxter International Inc. (BAX) CEO Joe Almeida on Q2 2021 Results - Earnings Call Transcript
- 07/29/2021
|
Baxter Q2 Earnings Marginally Beat Estimates; Revises Upper End Of 2021 EPS Outlook
- Baxter International Inc (NYSE: BAX) Q2 revenue of $3.1 billion, in line with the consensus, increased 14% on a reported basis, 9% on a constant currency basis, and 8% on an operational basis. Adjusted EPS of $0.80 increased 25% and surpassed the estimate of $0.75.
- 07/29/2021
|
Baxter Reports Second-Quarter 2021 Results
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the second quarter of 2021. “As markets worldwide continue to cope with the effects from the COVID-19 pandemic, Baxter's second quarter performance reflects the diversity and durability of our lifesaving portfolio combined with the breadth of our geographic reach,” said José (Joe) E. Almeida, chairman, president and chief executive officer. “Our drive to
- 07/29/2021
|
Why the Earnings Surprise Streak Could Continue for Baxter (BAX)
- Baxter (BAX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- 07/28/2021
|
Hill Rom Stock Shoots Higher As Baxter In Early Talks To Acquire Company: WSJ
- According to people familiar with the matter, Baxter International Inc (NYSE: BAX) is reportedly in talks to buy Hill-Rom Holdings Inc (NYSE: HRC). The talks are at an early stage, some of the people said, and there's no guarantee a deal will be reached.
- 07/28/2021
|
Baxter (BAX) to Report Q2 Earnings: What's in the Cards?
- Baxter's (BAX) second-quarter results are likely to reflect growth in its Acute Therapies business.
- 07/23/2021
|
Pre-August Billionaire Flash: 63 Stocks, 41 Dividends, 3 Buys
- Kiplinger Investing publishes opportune buy-lists for investors online. Two billionaire stock-lists by Dan Burrows included 50 published 12/8/20, with 30 more out June 1, 2021. Seventeen were duplicated, leaving 63. 41 of these 63 billionaire-held stocks pay dividends. As of 7/20/21, the top-ten ranged 2.52%-6.22% by annual yield and ranged 23.13%-52.70% per broker-estimated price-target upsides.
- 07/22/2021
|
Baxter Declares Quarterly Dividend
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that its Board of Directors has declared a quarterly cash dividend of $0.28 per share of common stock. The dividend is payable on October 1, 2021, to shareholders of record as of September 3, 2021. The indicated annual dividend rate is $1.12 per share of common stock. About Baxter Every day, millions of patients and caregivers rely on Baxter's leading portfolio of c
- 07/12/2021
|
Child Health in Focus in Face of Delta Strain Threat: 3 Picks
- Here are three stocks, BAX, BRBR, and MRVI with a favorable Zacks Rank and huge prospects in child healthcare at present.
- 07/02/2021
|
Cybersecurity Gains Prominence in Healthcare: 3 Stocks to Watch
- Here we look at three stocks, VEEV, HSIC and BDX, that investors can keep a watch on the back of their robust cybersecurity measures.
- 06/17/2021
|
Baxter to Host Second-Quarter 2021 Financial Results Conference Call for Investors
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its second-quarter 2021 financial results on Thursday, July 29, 2021 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/8371319 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter
- 06/15/2021
|
Baxter's (BAX) Theranova-Enabled HDx Therapy Data Positive
- Baxter's (BAX) Theranova-enabled HDx therapy is likely to boost clinical outcomes and lower healthcare resource utilization.
- 06/09/2021
|
Baxter (BAX) Unveils New Digital Health Module for PD Patients
- Baxter (BAX) introduces new clinical management resource within the Sharesource remote patient management platform for home dialysis patients.
- 06/07/2021
|
Baxter's (BAX) PrisMax 2 to Simplify Organ Support Therapies
- Baxter's (BAX) PrisMax 2 aims to enhance user experience and help in addressing the unique demands of the ICU.
- 06/01/2021
|
Baxter Increases Dividend and Declares Quarterly Dividend
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced an increase in the company's quarterly cash dividend to a rate of $0.28 per share of common stock. This represents an approximately 14% increase over the previous quarterly dividend rate of $0.245 per share. Baxter's Board of Directors declared the dividend payable on July 1, 2021, to stockholders of record as of June 4, 2021. The indicated annual dividend rate is n
- 05/03/2021
|
Baxter International Inc.'s (BAX) CEO Joe Almeida on Q1 2021 Results - Earnings Call Transcript
- Baxter International Inc.'s (BAX) CEO Joe Almeida on Q1 2021 Results - Earnings Call Transcript
- 04/29/2021
|
Baxter International (BAX) Q1 Earnings and Revenues Top Estimates
- Baxter (BAX) delivered earnings and revenue surprises of 18.75% and 1.73%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 04/29/2021
|
Baxter Reports First-Quarter 2021 Results
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the first quarter of 2021. “Baxter's medically essential products are fundamental to healthcare, and many have proven pivotal in the fight against COVID-19,” said José (Joe) E. Almeida, chairman, president and chief executive officer. “Our life-sustaining portfolio, broad geographic reach and the ongoing momentum of our business transformation are all key
- 04/29/2021
|
Baxter (BAX) to Report Q1 Earnings: What's in the Cards?
- Baxter's (BAX) first-quarter results are likely to reflect growth in its Acute Therapies business.
- 04/26/2021
|
Baxter to Present at the BofA Securities 2021 Virtual Health Care Conference
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the BofA Securities 2021 Virtual Health Care Conference on Tuesday, May 11, 2021. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 8:45 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through August 11, 2021. About Baxter Every day, millions of patients and careg
- 04/07/2021
|
Baxter To Host Its Annual Meeting Of Stockholders In Virtual Format
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that, due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic, its Annual Meeting of Stockholders (the 2021 Annual Meeting) will again be held by means of a virtual format only. The 2021 Annual Meeting will be held on Tuesday, May 4, 2021 at 9 a.m., Central Time, as disclosed in Baxter's proxy statement for the meeting. Onli
- 03/30/2021
|
Baxter to Host First-Quarter 2021 Financial Results Conference Call for Investors
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its first-quarter 2021 financial results on Thursday, April 29, 2021 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/1693119 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter
- 03/24/2021
|
Baxter (BAX) Receives FDA Nod for AK 98 Hemodialysis Machine
- Baxter (BAX) gets FDA approval for its AK 98 Hemodialysis machine that offers a compact, portable and easy-to-use system for dialysis providers.
- 03/16/2021
|
Baxter Announces U.S. FDA 510(k) Clearance of AK 98 Hemodialysis Machine
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global innovator in renal care, today announced U.S. Food and Drug Administration (FDA) clearance of its next-generation Artificial Kidney 98 (AK 98) dialysis machine, which is designed to be a portable and easy-to-use system to administer hemodialysis (HD) treatments. AK 98 offers encrypted, two-way connectivity, which enables the system to pull prescriptions directly from the electronic medical record (EMR) for simplifi
- 03/12/2021
|
Recovering Trauma Cases Should Highlight AxoGen's Improving Execution
- Recovering Trauma Cases Should Highlight AxoGen's Improving Execution
- 03/11/2021
|
Baxter to Present at Oppenheimer 31st Annual Healthcare Conference
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 10:40 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through September 13, 2021. About Baxter Every day, millions of patients and car
- 03/10/2021
|
Baxter to provide sterile manufacturing, packaging for Moderna's COVID-19 vaccine
- Baxter International Inc. announced Monday an agreement with Moderna Inc. , in which Baxter will provide sterile manufacturing services and supply packaging for 60 million to 90 million doses of Moderna's COVID-19 vaccine. Baxter's stock is little changed in premarket trading, while Moderna shares fell 1.4%.
- 03/08/2021
|
Top 4 4th-Quarter Buys of Al Gore's Generation Investment Management
- Generation Investment Management, the firm co-founded by Al Gore (Trades, Portfolio) and David Blood, disclosed this month that its top four buys during the fourth quarter of 2020 included a new position in Alibaba Group Holding Ltd. (NYSE:BABA) and boosts to its Equifax Inc. (NYSE:EFX), Baxter International Inc. (NYSE:BAX) and Illumina Inc. (NASDAQ:ILMN) holdings.
- 02/26/2021
|
Why It's Time To Rotate Back To Baxter International
- Baxter is a moat-worthy healthcare innovation company and ended 2020 with revenue growth. Its shares are still down from a year ago, and I see it as being a solid recovery play.
- 02/25/2021
|
Baxter Appoints Dr. David Wilkes to Its Board and Albert Stroucken as Lead Independent Director
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced it has appointed David S. Wilkes, M.D., dean, University of Virginia School of Medicine, and co-founder and chief scientific officer of biotech start-up ImmuneWorks Inc., to its board of directors. Dr. Wilkes will serve on Baxter's Quality, Compliance and Technology Committee. Additionally, Baxter has appointed Albert P.L. Stroucken, former executive chairman and ch
- 02/16/2021
|
Baxter International's (BAX) CEO Jose Almeida on Q4 2020 Results - Earnings Call Transcript
- Baxter International's (BAX) CEO Jose Almeida on Q4 2020 Results - Earnings Call Transcript
- 02/04/2021
|
Baxter (BAX) Q4 Earnings and Revenues Surpass Estimates
- Baxter's (BAX) fourth-quarter results reflect robust performance across five of its business units.
- 02/04/2021
|
Baxter International (BAX) Q4 Earnings and Revenues Surpass Estimates
- Baxter (BAX) delivered earnings and revenue surprises of 5.26% and 0.83%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 02/04/2021
|
Recap: Baxter International Q4 Earnings
- Shares of Baxter International (NYSE:BAX) moved higher by 0.3% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 1700.00% over the past year to $0.80, which beat the estimate of $0.76.
- 02/04/2021
|
Baxter Reports Fourth-Quarter and Full-Year 2020 Results
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the fourth quarter and full year ended December 31, 2020, and provided its financial guidance for 2021. “Amid an unprecedented global public health crisis, Baxter remains focused on advancing our Mission for patients and driving value for all stakeholders,” said José (Joe) E. Almeida, chairman, president and chief executive officer. “Our 2020 performance
- 02/04/2021
|
Baxter (BAX) to Report Q4 Earnings: What's in the Cards?
- Baxter's (BAX) fourth-quarter performance is likely to reflect growth in its Acute Therapies business.
- 02/01/2021
|
Analysts Estimate Baxter International (BAX) to Report a Decline in Earnings: What to Look Out for
- Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 01/28/2021
|
Baxter to Present at SVB Leerink 10th Annual Global Healthcare Conference
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 10:40 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through May 25, 2021. About Baxter Every day, millions of patients and
- 01/21/2021
|
This Medical Device Maker Will Be Well Positioned Post COVID
- The pandemic is only a temporary setback for this diversified global manufacturer of medical devices.
- 01/21/2021
|
5 Health Care Stocks Gurus Are Buying
- According to the GuruFocus All-in-One Screener as of Jan. 15, the following Health Care stocks are popular among gurus.
- 01/15/2021
|
Baxter Is A Better Choice Than Boston Scientific Stock
- We think that Baxter International currently is a better pick compared to Boston Scientific. BAX stock trades at about 3.6x trailing Revenues, compared to around 5.2x for Boston Scientific.
- 01/13/2021
|
Baxter to Host Fourth-Quarter 2020 Financial Results Conference Call for Investors
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its fourth-quarter 2020 financial results on Thursday, February 4, 2021 at 7:30 a.m. Central Time. To participate in this conference call please follow this link http://www.directeventreg.com/registration/event/5044187 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Bax
- 01/05/2021
|
Baxter Stock Can Offer 15% Upside
- We believe that Baxter stock, a healthcare supply company, is a good buying opportunity at the present time. BAX stock trades near $80 currently and it is, in fact, down 16% from its pre-Covid high of $93 in February 2020 – just before the coronavirus pandemic hit the world.
- 12/17/2020
|
Baxter to Present at the 39th Annual J.P. Morgan Healthcare Conference
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the 39th Annual J.P. Morgan Healthcare Conference via webcast. José (Joe) E. Almeida, Baxter's chairman and chief executive officer, is scheduled to present on Monday, January 11, 2021 at 9:10 a.m. Eastern Time. The live webcast of Baxter's presentation, along with accompanying slides, can be accessed at www.baxter.com and will be available for replay through Februa
- 12/16/2020
|
Baxter (BAX) Announces Site Expansion to Improve Patient Care
- Baxter's (BAX) latest site expansion is aimed at better serving its client and patient pool along with employment creation.
- 11/30/2020
|
Baxter (BAX) Gets FDA Nod for Homechoice Claria APD System
- Baxter's (BAX) Homechoice Claria combines a simple user interface with the benefits of Sharesource.
- 11/26/2020
|
Baxter Is Poised For A Breakout Given Strong Fundamentals And An Aging Population
- BAX offers a broad portfolio of essential, life-saving healthcare products to treat acute and chronic illnesses. There is no other competitor in the space that competes with BAX in all of their businesses.
- 11/23/2020
|
Baxter to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the Evercore ISI 3rd Annual HealthCONx virtual conference via webcast on Tuesday, December 1, 2020. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 11:20 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through May 30, 2021. About Baxter Every day, millions of pa
- 11/18/2020
|
Baxter International Inc. (BAX) CEO Jose Almeida on Q3 2020 Results - Earnings Call Transcript
- Baxter International Inc. (BAX) CEO Jose Almeida on Q3 2020 Results - Earnings Call Transcript
- 10/29/2020
|
Baxter Announces Proposed $650 Million Senior Notes Offering
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that it proposes to offer, subject to market conditions and other factors, $650 million aggregate principal amount of senior notes due 2031 (the “Notes”). The Notes will be offered and sold only to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States, only to non-U.
- 10/29/2020
|
Baxter Reports Third-Quarter 2020 Results
- DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported earnings for the third quarter of 2020 and updated its outlook for full-year 2020. “Baxter's third-quarter performance reflects ongoing demand for our medically essential products as well as the company's agility and resilience amid a historic public health crisis,” said José (Joe) E. Almeida, chairman and chief executive officer. “Our multiyear transformation has po
- 10/29/2020
|
Becton Dickinson Trying To Leverage COVID-19 Opportunities While Fixing Some Longer-Term Issues
- BD management has had to deal with new revenue headwinds from COVID-19 while also trying to resolve longer-standing issues like the Alaris pump recalls.
- 09/14/2020
|
IPO Update: Outset Medical Finalizes Terms For IPO
- Outset Medical intends to raise $175 million in a U.S. IPO.
- 09/11/2020
|
Tracking Al Gore's Generation Investment Management Portfolio - Q2 2020 Update
- Generation Investment Management’s 13F portfolio value increased from $14.09B to $17.34B this quarter.
- 09/09/2020
|
Baxter Is Largely Defensive: Hide In Baxter, But Don't Speculate
- BAX has a solid product line and impressive pricing power, but large operations and development risks to match.
- 09/09/2020
|
Tracking Larry Robbins' Glenview Capital Management Portfolio - Q2 2020 Update
- Glenview Capital Management's 13F portfolio value decreased from $3.68B to $3.63B this quarter. The number of positions decreased from 44 to 43.
- 09/04/2020
|
Bullish On Baxter: Cruising Along, Business As Usual; $90 Price Target Set
- Baxter continues to chug on slowly as it has done for the past 10 years, delivering ongoing value to shareholders.
- 08/28/2020
|
Tracking Dan Loeb's Third Point Portfolio - Q2 2020 Update
- Dan Loeb's 13F portfolio value increased from $6.27B to $7.30B this quarter. The number of positions increased from 30 to 36.
- 08/28/2020
|
Outset Medical Begins U.S. IPO Rollout
- Outset Medical has filed to raise $100 million in an IPO, although the final figure may differ. The firm is commercializing an improved hemodialysis machine.
- 08/24/2020
|
Daniel Loeb's Top 6 Trades in the 2nd Quarter
- Activist investor reduces top-holding Baxter, buys 2 Chinese retail stocks
- 08/19/2020
|
Baxter to Present at the 2020 Wells Fargo Virtual Healthcare Conference
- Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the 2020 Wells Fargo Virtual Healthcare Conference via webcast on Wednesday, September 9, 2020. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 10:00 a.m. Eastern Time.
- 08/19/2020
|
BMEZ: Continuing To Weather The Pandemic Storm
- BMEZ is a fund that is focused on the healthcare space, more specifically, a focus on the health sciences industry.
- 08/19/2020
|
Baxter (BAX) Receives EUA for Regiocit Replacement Solution
- Baxter (BAX) receives EUA from the FDA for Regiocit, which is the only authorized citrate-based replacement solution for use in CRRT during the COVID-19 pandemic.
- 08/17/2020
|
Baxter Gets FDA Emergency Use Nod For Regiocit During Covid-19 Pandemic
- Baxter International has been granted Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for its Regiocit, to be used during the coronavirus pandemic as a replacement solution only in adult patients suffering from acute kidney injury.Baxter (BAX) said that under the EUA, Regiocit is now authorized to be used in adult patients being treated with continuous renal replacement therapy (CRRT) and for whom regional citrate anticoagulation is appropriate during the COVID-19 pandemic.Acute kidney injury, a potentially life-threatening condition where the kidneys suddenly stop working and fluid and uremic toxins build up in the body, is one of many complications affecting COVID-19 patients. CRRT mimics many of the functions of the natural kidney and is the cornerstone of treatment in patients with severe acute kidney injury. Regiocitis the only authorized citrate-based replacement solution available in the US for use in CRRT during the COVID-19 pandemic, Baxter said.“Demand for CRRT remains elevated as the COVID-19 pandemic continues to progress, and we’re proud to offer Regiocitas an important new option to help healthcare providers in the US optimize care for critically ill patients requiring CRRT and regional citrate anticoagulation, while bringing an additional supply of replacement solutions to the US,” said Reaz Rasul, general manager of Baxter’s Acute Therapies business.Regiocitcontains physiological concentrations of sodium (140 mmol/l), chloride (86 mmol/l) and a low concentration of citrate (18 mmol/L) and can provide the necessary pre-filter volumes required to replace filtration losses during convective therapies. It is used in combination with other standard dialysis and replacement solutions that supplement missing electrolytes such as potassium, magnesium and phosphate.Deerfield, Illinois-based Baxter added that it continues to provide CRRT machines, fluids and sets to help healthcare facilities address patient needs around the world.Regiocit has not been approved by the FDA in the US but is currently in use in countries around the world, including in Europe and Asia. A limited initial shipment will be available in the US immediately, with more significant production ramping up throughout the coming weeks and months, the company said.Baxter shares advanced 1.6% in Friday’s after-market session and are now trading little changed from their start of the year level. The $96.14 average analyst price target indicates 15% upside potential in the shares over the coming 12 months.Credit Suisse analyst Matt Miksic last week reiterated a Buy rating on the stock with a $99 price target, saying that he views the stock as attractive at current levels, trading significantly below its 3-year average multiple relative to the S&P 500.“Strength in Acute Therapies is expected to continue, driven mostly by consumable growth and utilization related to COVID-19, with some deceleration in 2H vs. 1H,” Miksic wrote in a note to investors.Overall Wall Street analysts share Miksic’s bullish outlook. The Strong Buy consensus boasts 6 Buys versus 3 Holds. (See Baxter stock analysis on TipRanks)Related News: Novavax Pops 7% On South Korea Deal For Global Covid-19 Vaccine Supply EU Secures 200M Doses Of Johnson & Johnson’s Covid-19 Vaccine Candidate Quidel’s Lyra Covid-19 Test Gets Nod For Sale In Canada; Shares Rise 6% More recent articles from Smarter Analyst: * Alibaba’s Ant Group Starts Filing Process For Blockbuster China IPO * Buffett’s Berkshire Builds Position In Barrick Gold, Says Goodbye To US Banks * Barclays Cuts Micron's PT On Chip Demand Woes * Baidu Takes Buyback Program To $3B; Stock Down 6% Post-Print
- 08/16/2020
|
Baxter Obtains U.S. FDA Emergency Use Authorization for Regiocit Replacement Solution Used in CRRT
- Baxter International Inc. (NYSE:BAX), a global leader in acute care, announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for Regiocit, the company’s replacement solution that contains citrate for regional citrate anticoagulation of the extracorporeal circuit. Under the EUA, Regiocit is authorized to be used as a replacement solution only in adult patients being treated with continuous renal replacement therapy (CRRT) and for whom regional citrate anticoagulation is appropriate during the COVID-19 pandemic.
- 08/14/2020
|
Tracking Tweedy Browne Portfolio - Q2 2020 Update
- Tweedy Browne’s 13F portfolio value increased from $2.15B to $2.51B this quarter. The largest five individual stock positions are Alphabet, Berkshire Hathaway, Johnson & Johnson, Cisco Systems, and Baidu, and they account for ~55% of the portfolio.
- 08/12/2020
|
Baxter Obtains U.S. FDA Emergency Use Authorizations for HF20 Set and ST Set Used in CRRT During Covid-19 Pandemic
- Baxter International Inc. (NYSE:BAX), a global leader in acute care, announced it has received Emergency Use Authorizations (EUAs) from the U.S. Food and Drug Administration (FDA) for the company’s HF20 Set and ST Set used in continuous renal replacement therapy (CRRT). Under its EUA, the HF20 Set is authorized to deliver CRRT to treat patients of low weight (8-20 kg) and low blood volume who cannot tolerate a larger extracorporeal circuit volume in an acute care environment during the COVID-19 pandemic. The ST Set is authorized for use under its EUA to provide CRRT to treat patients in an acute care environment during the COVID-19 pandemic. Both the HF20 Set and ST Set can be used with the Prismaflex or PrisMax control units (monitors).
- 08/12/2020
|
Global Chemotherapy-induced Nausea and Vomiting Drugs Market 2020-2024: Anticipated to Grow by $525 Million - ResearchAndMarkets.com
|
North American Automated Compounding Systems Market Outlook to 2027 and Impact of COVID-19 on the Industry - ResearchAndMarkets.com
|
Insights on the Global Alcohol Prep Pads Market 2020-2024 | COVID-19 Analysis, Drivers, Restraints, Opportunities and Threats | Technavio
- The Global Alcohol Prep Pads Market will grow by USD 160.61 mn during 2020-2024
- 08/07/2020
|
COVID-19 Impacts: Heparin Market will Accelerate at a CAGR of almost 3% through 2020-2024 | Increasing Prevalence of Chronic Conditions to Boost Growth | Technavio
|
COVID-19 Impacts: Heparin Market will Accelerate at a CAGR of almost 3% through 2020-2024 | Increasing Prevalence of Chronic Conditions to Boost Growth | Technavio
- The Global Heparin Market will grow by USD 941.2 mn during 2020-2024
- 08/06/2020
|
Baxter Introduces Virtual Peritoneal Dialysis Excellence Academy for Nurses in the U.S.
- Baxter International, Inc. (NYSE:BAX), a global innovator in renal care, announced today the launch of the PD Excellence Academy, a new virtual training platform and educational resource center to help nurses develop their PD skills to deliver optimal patient care. The platform also offers a benefit to employers, including dialysis clinic administrators and nephrologists, who now have an additional resource available to develop and retain talent. As home dialysis rates continue to rise, so does the demand for nurses who have the expertise to successfully manage a PD program.
- 08/05/2020
|
Analysts Expect Baxter International Inc (NYSE:BAX) Will Post Quarterly Sales of $2.92 Billion
- Wall Street brokerages expect that Baxter International Inc (NYSE:BAX) will report $2.84 billion in sales for the current quarter, Zacks Investment Research reports. Eight analysts have made estimates for Baxter International’s earnings, with estimates ranging from $2.77 billion to $2.95 billion. The firm is expected to announce its next quarterly earnings report on Thursday, October […]
- 08/05/2020
|
Vident Investment Advisory LLC Has $900,000 Stake in Baxter International Inc (NYSE:BAX)
- Vident Investment Advisory LLC boosted its holdings in shares of Baxter International Inc (NYSE:BAX) by 24.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,453 shares of the medical instruments supplier’s stock after buying an additional 2,078 shares during the quarter. Vident Investment […]
- 08/04/2020
|
Global Medical Nutrition Market to Surpass US$ 17.9 Billion by 2027, Says Coherent Market Insights
- North America is expected to hold a dominant position in the global market during the forecast period 2020-2027.
- 08/04/2020
|
Ligand Reports Second Quarter 2020 Financial Results
- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ending June 30, 2020 and provided an
- 08/03/2020
|
Intact Investment Management Inc. Decreases Stock Position in Baxter International Inc (NYSE:BAX)
- Intact Investment Management Inc. trimmed its holdings in shares of Baxter International Inc (NYSE:BAX) by 30.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,000 shares of the medical instruments supplier’s stock after selling 2,600 shares during the quarter. […]
- 08/01/2020
|
Raymond James & Associates Lowers Stock Holdings in Baxter International Inc (NYSE:BAX)
- Raymond James & Associates reduced its position in Baxter International Inc (NYSE:BAX) by 9.9% in the 2nd quarter, Holdings Channel reports. The fund owned 247,691 shares of the medical instruments supplier’s stock after selling 27,108 shares during the period. Raymond James & Associates’ holdings in Baxter International were worth $21,326,000 at the end of the […]
- 08/01/2020
|
Analysts Offer Insights on Healthcare Companies: Baxter International (NYSE: BAX), Cigna (NYSE: CI) and Vertex Pharmaceuticals (NASDAQ: VRTX) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Baxter International
- 07/31/2020
|
If You Had Bought Baxter International (NYSE:BAX) Shares Five Years Ago You'd Have Earned105% Returns
- When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far...
- 07/31/2020
|
Baxter International Inc (BAX) Q2 2020 Earnings Call Transcript
- BAX earnings call for the period ending June 30, 2020.
- 07/30/2020
|
Baxter International's (BAX) CEO Joe Almeida on Q2 2020 Results - Earnings Call Transcript
- Baxter International Inc. (NYSE:BAX) Q2 2020 Earnings Conference Call July 30, 2020 8:30 AM ET Company Participants Clare Trachtman – Vice President-Investor Relations Joe Almeida – Chairman and Chief Executive Officer Jay Saccaro – Chief Financial Officer Conference Call Participants Robbie Marcus – JPMorgan David Lewis – Morgan Stanley Pito Chickering – Deutsche Bank Bob Hopkins – Bank of America Vijay Kumar – Evercore ISI Matt Taylor – UBS Joanne Wuensch – Citi Research Larry Biegelsen – Wells Fargo Presentation Operator Good morning, ladies and gentlemen, and welcome to Baxter International’s Second Quarter 2020 Earnings Conference Call.
- 07/30/2020
|
Baxter (BAX) Earnings and Revenues Miss Estimates in Q2
- Baxter's (BAX) second-quarter earnings reflect weak performance across Medication Delivery, Pharmaceutical and Advanced Surgery business units and contraction in margins.
- 07/30/2020
|
Baxter International Inc. 2020 Q2 - Results - Earnings Call Presentation
- The following slide deck was published by Baxter International Inc. in conjunction with their 2020 Q2 earnings call..
- 07/30/2020
|
Baxter Reports Second-Quarter 2020 Results
- Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the second quarter of 2020 and provided its outlook for full-year 2020.
- 07/30/2020
|
Earnings Scheduled For July 30, 2020
- Companies Reporting Before The Bell
• Mastercard Inc. (NYSE:MA) is expected to report quarterly earnings at $1.16 per share on revenue of $3.23 billion.
• Moody's...
- 07/30/2020
|
Medical Products Stock Earnings on Jul 30: BAX, SYK & More
- Despite the impact of the pandemic on the second quarter, Medical Product companies have shown strength on the back of huge adoption of COVID-19 related healthcare-support products and services.
- 07/29/2020
|
Baxter and Ayogo Announce Partnership for Unique Digital Health Solutions for Home Dialysis
- Baxter International Inc. (NYSE:BAX), a global innovator in renal care, and Ayogo Health Inc., a behavioral science-based digital health company, announced the expansion of their partnership to support the needs of patients with kidney disease through digital health solutions. Ayogo is combining LifePlan—its unique behavior-based digital platform—with Baxter’s expertise in renal care to build mobile apps and digital solutions that bring personalized, relevant and timely support to patients with kidney failure. Baxter also made an equity investment in Ayogo in exchange for minority interest in the company. Financial details of the agreement were not disclosed.
- 07/29/2020
|
Baxter (BAX) to Report Q2 Earnings: What's in the Cards?
- Baxter's (BAX) second-quarter performance is likely to reflect growth in its five global business units.
- 07/27/2020
|
Palisade Asset Management LLC Trims Stock Holdings in Baxter International Inc (NYSE:BAX)
- Palisade Asset Management LLC cut its holdings in Baxter International Inc (NYSE:BAX) by 1.2% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 96,506 shares of the medical instruments supplier’s stock after selling 1,135 shares during the quarter. Baxter International comprises approximately 1.3% […]
- 07/27/2020
|
Baxter International Inc (NYSE:BAX) Shares Sold by Ziegler Capital Management LLC
- Ziegler Capital Management LLC cut its stake in Baxter International Inc (NYSE:BAX) by 37.9% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 89,871 shares of the medical instruments supplier’s stock after selling 54,761 shares during the period. Ziegler Capital Management LLC’s holdings in Baxter International […]
- 07/27/2020
|
Baxter and VIPUN Medical Announce Collaboration to Commercialize Innovative Gastric Monitoring System to Help Enhance Clinical Nutrition
- Baxter International Inc. and VIPUN Medical today announced an agreement to commercialize the VIPUN Gastric Monitoring System.
- 07/24/2020
|
Baxter International Inc (NYSE:BAX) Shares Acquired by Empirical Finance LLC
- Empirical Finance LLC lifted its holdings in shares of Baxter International Inc (NYSE:BAX) by 14.7% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 3,341 shares of the medical instruments supplier’s stock after buying an additional 429 shares during the period. Empirical Finance LLC’s holdings in Baxter International were worth $288,000 at the end […]
- 07/22/2020
|
Valeo Financial Advisors LLC Trims Stock Holdings in Baxter International Inc (NYSE:BAX)
- Valeo Financial Advisors LLC trimmed its position in Baxter International Inc (NYSE:BAX) by 4.7% during the 2nd quarter, Holdings Channel.com reports. The firm owned 4,480 shares of the medical instruments supplier’s stock after selling 220 shares during the period. Valeo Financial Advisors LLC’s holdings in Baxter International were worth $386,000 as of its most recent […]
- 07/22/2020
|
Insights on the Worldwide Apheresis Industry to 2026 - Key Drivers, Restraints and Opportunities - ResearchAndMarkets.com
|
Trust Co. of Vermont Sells 297 Shares of Baxter International Inc (NYSE:BAX)
- Trust Co. of Vermont decreased its stake in Baxter International Inc (NYSE:BAX) by 9.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,804 shares of the medical instruments supplier’s stock after selling 297 shares during the period. Trust Co. of Vermont’s holdings in […]
- 07/19/2020
|
Baxter International Inc (NYSE:BAX) Stock Position Decreased by Heritage Wealth Advisors
- Heritage Wealth Advisors decreased its position in Baxter International Inc (NYSE:BAX) by 40.9% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 700 shares of the medical instruments supplier’s stock after selling 485 shares during the quarter. Heritage Wealth Advisors’ holdings in Baxter […]
- 07/19/2020
|
Raymond James Trust N.A. Increases Stake in Baxter International Inc (NYSE:BAX)
- Raymond James Trust N.A. increased its position in shares of Baxter International Inc (NYSE:BAX) by 36.4% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 18,357 shares of the medical instruments supplier’s stock after purchasing an additional 4,900 shares during the period. Raymond James Trust N.A.’s holdings in Baxter International were worth $1,580,000 as […]
- 07/18/2020
|
Baxter International Inc (NYSE:BAX) Stock Holdings Lessened by Welch & Forbes LLC
- Welch & Forbes LLC reduced its stake in shares of Baxter International Inc (NYSE:BAX) by 4.7% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 3,410 shares of the medical instruments supplier’s stock after selling 168 shares during the quarter. Welch & Forbes LLC’s holdings in Baxter International were worth $294,000 as of its most […]
- 07/18/2020
|
Baxter International Inc (NYSE:BAX) Shares Sold by North Star Investment Management Corp.
- North Star Investment Management Corp. decreased its holdings in shares of Baxter International Inc (NYSE:BAX) by 10.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,971 shares of the medical instruments supplier’s stock after selling 727 shares during the […]
- 07/18/2020
|
Baxter International Inc (NYSE:BAX) Shares Sold by Tiaa Fsb
- Tiaa Fsb reduced its holdings in Baxter International Inc (NYSE:BAX) by 0.7% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,037 shares of the medical instruments supplier’s stock after selling 172 shares during the quarter. Tiaa Fsb’s holdings in Baxter […]
- 07/17/2020
|
COVID-19 Impact and Recovery Analysis- Medical Devices Market In Japan 2020-2024 | Sophisticated Healthcare Infrastructure Along With Favorable Government Initiatives to Boost Growth | Technavio
- The medical devices market size in Japan will grow by USD 6.65 billion during 2020-2024
- 07/17/2020
|
Envestnet Asset Management Inc. Sells 25,126 Shares of Baxter International Inc (NYSE:BAX)
- Envestnet Asset Management Inc. cut its holdings in shares of Baxter International Inc (NYSE:BAX) by 17.5% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 118,525 shares of the medical instruments supplier’s stock after selling 25,126 shares during the period. […]
- 07/16/2020
|
Ligand’s Second Quarter Financial Results to be Reported August 3rd
- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report second quarter 2020 financial results on August 3, 20
- 07/16/2020
|
Baxter Ranks in Top 10% on 2020 Disability Equality Index
- Baxter International Inc. (NYSE:BAX), a leading global medical products company, announced today it has been named a top-scoring company on the 2020 Disability Equality Index® (DEI) by Disability:IN, the leading nonprofit resource for business disability inclusion worldwide. The company’s 90% score places it in the top 10% of all companies in the index and earns the "Best Place to Work for Disability Inclusion" recognition. The DEI ranks companies across six categories: culture and leadership, enterprise-wide access, employment practices, community engagement, supplier diversity and non-U.S. operations.
- 07/15/2020
|
Baxter Ranks in Top 10% on 2020 Disability Equality Index
- Baxter International Inc. (NYSE:BAX), a leading global medical products company, announced today it has been named a top-scoring company on the 2020 D
- 07/15/2020
|
Baxter Declares Quarterly Dividend
- Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that its Board of Directors has declared a quarterly cash dividend of $0.245 per share of common stock. The dividend is payable on October 1, 2020, to shareholders of record as of August 31, 2020. The indicated annual dividend rate is $0.98 per share of common stock.
- 07/14/2020
|
Baxter International Inc (NYSE:BAX) Shares Sold by IFM Investors Pty Ltd
- IFM Investors Pty Ltd lowered its stake in Baxter International Inc (NYSE:BAX) by 22.9% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 36,712 shares of the medical instruments supplier’s stock after selling 10,931 shares during the quarter. IFM Investors Pty Ltd’s holdings in Baxter International were […]
- 07/14/2020
|
Baxter Declares Quarterly Dividend
- Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that its Board of Directors has declared a quarterly
- 07/14/2020
|
$2.86 Billion in Sales Expected for Baxter International Inc (NYSE:BAX) This Quarter
- Wall Street analysts expect Baxter International Inc (NYSE:BAX) to post sales of $2.86 billion for the current quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Baxter International’s earnings. The highest sales estimate is $2.90 billion and the lowest is $2.80 billion. Baxter International posted sales of $2.84 billion during the same quarter […]
- 07/13/2020
|
Exane Derivatives Boosts Holdings in Baxter International Inc (NYSE:BAX)
- Exane Derivatives grew its holdings in Baxter International Inc (NYSE:BAX) by 36,922.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,332 shares of the medical instruments supplier’s stock after purchasing an additional 3,323 shares during the quarter. Exane Derivatives’ holdings in Baxter […]
- 07/12/2020
|
Baxter International (NYSE:BAX) vs. AIT Therapeutics (NYSE:AITB) Financial Comparison
- AIT Therapeutics (OTCMKTS:AITB) and Baxter International (NYSE:BAX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends. Risk and Volatility AIT Therapeutics has a beta of -0.31, suggesting that its share price is […]
- 07/12/2020
|
Baxter Gets FDA Nod for Altapore Shape Bioactive Bone Graft
- Baxter (BAX) receives FDA approval for Altapore Shape that will provide surgeons versatile options to advance the art of healing and boost clinical outcomes during a surgery.
- 07/10/2020
|
Baxter Gets FDA Nod for Altapore Shape Bioactive Bone Graft
- Stocks Analysis by Zacks Investment Research covering: Baxter International Inc, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, West Pharmaceutical Services Inc. Read Zacks Investment Research's latest article on Investing.com
- 07/10/2020
|
Baxter to Host Second-Quarter 2020 Financial Results Conference Call for Investors
- Baxter International Inc. (NYSE:BAX), a leading global medical products company, will host a conference call to discuss its second-quarter 2020 financial results on Thursday, July 30, 2020, at 7:30 a.m. Central Time.
- 07/09/2020
|
Baxter Announces U.S. FDA Clearance of Altapore Shape Bioactive Bone Graft for Use in Surgery
- Baxter International Inc. today announced U.S. Food and Drug Administration (FDA) clearance of Altapore Shape Bioactive Bone Graft.
- 07/09/2020
|
Were Hedge Funds Right About Piling Into Baxter International Inc. (BAX)?
- How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
- 07/07/2020
|
Analysts Offer Insights on Healthcare Companies: Baxter International (NYSE: BAX), Translate Bio (NASDAQ: TBIO) and Intra-Cellular Therapies (NASDAQ: ITCI) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Baxter International
- 07/07/2020
|
Burden of COVID-19 on the Market & Rehabilitation Plan | Clinical Nutrition Market 2020-2024 | Rising Geriatric Population to Boost Growth | Technavio
- The Global Clinical Nutrition Market will grow by USD 21.47 mn during 2020-2024
- 07/07/2020
|
Global Surgical Retractor Market Set to Reach $3.6 Billion by 2026 - Breakdown by Product, Application and Region - ResearchAndMarkets.com
|
Global $6.3 Bn Pain Management Devices Market and Competition Analysis 2016-2026 - ResearchAndMarkets.com
|
Supreme Court Declines to Consider PTAB Authority to Overturn Article III Decisions
- On June 30, the U.S. Supreme Court denied certiorari to Chrimar Systems, Inc., thereby declining to consider the controversial issues of “when a judicial decision becomes binding on the parties, and whether a decree from a different branch of government can reverse an Article III court judgment.”
- 07/01/2020
|
Hemodialysis Equipment Market Analysis Highlights the Impact of COVID-19 2020-2024 | Shortage in Availability of Kidneys for Transplant to Augment Growth | Technavio
- The Global Hemodialysis Equipment Market will grow by USD 192.21 mn during 2020-2024
- 07/01/2020
|
Dividend Growth 50: Big Income Growth, Minimal Pandemic Peril
- The DG50 experienced no coronavirus-related dividend cuts during the first half of 2020. Year-over-year growth of the portfolio's income stream was outstanding.
- 06/30/2020
|
Analysis of COVID-19 Impact: Neuropathy Pain Treatment Market 2020-2024 | Presence of Large Patient Pool to Augment Growth | Technavio
- The Global Neuropathy Pain Treatment Market will grow by USD 1702.89 mn during 2020-2024
- 06/30/2020
|
Cramer adds new stocks, recommends buying 12 laggards in his Covid-19 index
- "When you look at the biggest winners in the index, they're overwhelmingly tech companies that help facilitate the stay-at-home economy, and a lot of these got hit today," the "Mad Money" host said.
- 06/29/2020
|
3 Stocks That Have Grown Earnings Fast
- Their 5-year EPS growth rates are higher than S&P; 500 Continue reading...
- 06/26/2020
|
Intravenous Fluid Bags Market 2020-2024 | Rising Prevalence Of Chronic Diseases To Boost Growth | Technavio
- The Global Intravenous Fluid Bags Market will grow by $ 667.51 mn during 2020-2024
- 06/26/2020
|
Baxter Publishes 2019 Corporate Responsibility Report, Highlighting Efforts to Make a Meaningful Difference as a Leading Global Corporate Citizen
- Baxter International Inc. (NYSE:BAX), a leading global medical products company, today released its 2019 Corporate Responsibility Report. The report, published annually, details progress towards realizing the company’s Corporate Responsibility priorities and goals, including driving the sustainability of products and operations, improving access to care for the underserved and fostering a best place to work. The report published today includes developments made in 2019 related to Baxter’s current set of five-year goals, which will conclude at the end of 2020.
- 06/25/2020
|
Dialysis Market to touch USD 177.56 Billion by 2027; Increasing Number of Renal Therapy Clinics Worldwide to Positively Impact the Market: Fortune Business Insights™
- The global dialysis market size is projected to reach USD 177.56 billion by 2027, exhibiting a CAGR of 7.7% during the forecast period. Complications caused in
- 06/25/2020
|
Drug Delivery Systems Market to Hit USD 45.20 Billion by 2027; Rising Demand for Efficient Drug Delivery for Complex Conditions to Fuel the Market: Fortune Business Insights™
- The global drug delivery systems market size is projected to reach USD 45.20 billion by 2027, exhibiting a CAGR of 6.8% during the forecast period. Increasing
- 06/25/2020
|
Insights & Forecast with Potential Impact of COVID-19 - Artificial Organs Market 2020-2024 | Increasing Prevalence of Chronic Disorders to Boost Growth | Technavio
- The Global Artificial Organs Market will grow by $ 11.07 bn during 2020-2024
- 06/25/2020
|
Baxter International (BAX) Receives a Buy from Oppenheimer - Markets
- In a report released today, Suraj Kalia from Oppenheimer initiated coverage with a Buy rating on Baxter International (BAX –
- 06/23/2020
|
Assessment of COVID-19's Effect on Heparin Market 2020-2024 | Increasing Prevalence of Chronic Conditions to Augment Growth | Technavio
|
Assessment of COVID-19's Effect on Hemostats and Tissue Sealants Market 2020-2024 | Use of Hemostats and Tissue Sealants in Surgeries to Augment Growth | Technavio
|
United Capital Financial Advisers LLC Sells 10,927 Shares of Baxter International Inc (NYSE:BAX)
- United Capital Financial Advisers LLC decreased its stake in shares of Baxter International Inc (NYSE:BAX) by 41.4% during the first quarter, HoldingsChannel reports. The firm owned 15,486 shares of the medical instruments supplier’s stock after selling 10,927 shares during the quarter. United Capital Financial Advisers LLC’s holdings in Baxter International were worth $1,257,000 at the […]
- 06/23/2020
|
Global Blood Market Assessment 2017-2028 Featuring Profiles of BD, Immucor, Roche Diagnostics, Baxter Int'l, Novartis, Ortho Clinical Diagnostics, Grifols Int'l, CSL Behring, and Novo Nordisk - ResearchAndMarkets.com
|
Crisis Boosts Cash Allure to Firms -- WSJ | MarketScreener
|
Les 50 futurs gagnants de l'économie mondiale à acheter en Bourse selon Goldman Sachs
- L'équipe de recherche de Goldman Sachs, dirigée par Peter Oppenheimer, a construit un portefeuille mondial de sociétés affichant des perspectives de croissance supérieures, les futurs gagnants de l'économie mondiale.
- 06/22/2020
|
During Coronavirus, Parents Face Fight for Right to See Care-Home Children
- Some pediatric-care facilities are telling families they must stay away from their children until the Covid lockdown is lifted. Most of the more than two million U.S. long-term care facility residents remain on lockdown, as they have been since mid-March.
- 06/21/2020
|
Cash Remains King as Companies Close a Dismal Second Quarter | MarketScreener
|
Cash Remains King as Companies Close a Dismal Second Quarter
- Cash remains king for large publicly traded U.S. companies adjusting to an economy and operations sharply changed by the coronavirus pandemic.
- 06/21/2020
|
The Global Catheter Securement Devices Market is expected to grow from USD 917.10 Million in 2019 to USD 1,243.87 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 5.21%
- Market Segmentation & Coverage: This research report categorizes the Catheter Securement Devices to forecast the revenues and analyze the trends in each of the following sub-markets:
- 06/20/2020
|
Assessment of COVID-19's Effect on Biosurgery Market 2020-2024 | Increasing Number of Surgical Procedures to Augment Growth | Technavio
|
Assessment of COVID-19's Effect on Programmable Infusion Pumps Market 2020-2024 | Growing Internet Connectivity in Programmable Infusion Pumps to Augment Growth | Technavio
- The Global Programmable Infusion Pumps Market will grow by USD 487.81 mn during 2020-2024
- 06/19/2020
|
Global Intravenous (IV) Therapy and Vein Access Market Insights, 2017 to 2028 - ResearchAndMarkets.com
|
Home Infusion Therapy Market to reach USD 86.89 Billion by 2027; Rise in Adoption of Advanced Technological Devices for Home Care to Drive the Market in North America, says Fortune Business Insights™
- The global home infusion therapy market size is likely to USD 86.89 billion by the end of 2027, owing to the increasing adoption of home medical services
- 06/16/2020
|
Elena Skvortsova nimmt ihre Tätigkeit als neues OMV Vorstandsmitglied für den Bereich Marketing & Trading auf
- Elena Skvortsova übernimmt als Chief Commercial Officer ab 15. Juni 2020 die Leitung des OMV Bereichs Downstream Marketing & Trading und ergänzt damit das OMV Executive Board als fünftes …
- 06/15/2020
|
Global Home Healthcare Market Trends Analysis Report 2020 - 2027 - ResearchAndMarkets.com
|
Analysts Offer Insights on Healthcare Companies: NuVasive (NASDAQ: NUVA), Sarepta Therapeutics (NASDAQ: SRPT) and Bluebird Bio (NASDAQ: BLUE) - Markets
- Analysts have been eager to weigh in on the Healthcare sector with new ratings on NuVasive (NUVA – Research Report),
- 06/12/2020
|
Global Bone Grafts and Substitutes Market Analysis and Forecast 2020-2025 - Increase in the Demand for Dental Bone Grafts - ResearchAndMarkets.com
|
Industry Report: Continuous Renal Replacement Therapy Market Share, Growth, Analysis and Size to surpass a $1.4 billion valuation by 2025
- Jun 11, 2020 (Market Insight Reports) --
Selbyville, Delaware According to Market Study Report, Provides A Detailed Overview Of Continuous Renal Replacement...
- 06/11/2020
|
Medical Devices Market By Device Type, End-Use, Size, Opportunities and Forecast, 2019 – 2026
- Jun 11, 2020 (Market Prediction via COMTEX) --
As per the research held by Acumen Research and Consulting, "the global Medical Devices market anticipated to...
- 06/11/2020
|
Global Bleeding Disorders Therapeutics Market 2020-2024 | Rising Initiatives To Increase Awareness to Boost Growth | Technavio
- The Global Bleeding Disorders Therapeutics Market will grow by $ 4.32 bn during 2020-2024
- 06/11/2020
|
Baxter Highlights New Data on the Role Technologies Play in Improving Care for Dialysis Patients During ERA-EDTA Virtual Congress
|
Baxter Highlights New Data on the Role Technologies Play in Improving Care for Dialysis Patients During the 57th ERA-EDTA Virtual Congress
- Baxter International Inc. (NYSE:BAX), a global innovator in renal care, today announced new data showing use of Baxter’s Sharesource remote patient management (telehealth) platform for automated peritoneal dialysis (APD) therapy performed in Colombia was associated with a 56% reduction in technique failure. In a separate study conducted in Canada, data show 74% of patients, who received expanded hemodialysis (HDx) therapy enabled by Theranova, self-reported an improved quality of life through better energy, sleep, appetite and/or reduced pain. These studies were among the many presented in support of scientific exchange during the 57th ERA-EDTA Virtual Congress, June 6-9.
- 06/10/2020
|
Special Report: COVID deepens the other opioid crisis - a shortage of hospital painkillers
- Special Report: COVID deepens the other opioid crisis - a shortage of hospital painkillers
- 06/09/2020
|
IPO Update: Vaxcyte Proceeds With IPO Plan (Pending:PCVX)
- Vaxcyte has filed proposed terms for its $210 million U.S. IPO. The firm is advancing a pipeline of vaccine candidates. PCVX is still an ultra early stage precl
- 06/08/2020
|
Monday Morning Market Highlights
- U.S. stocks advance, Thor Industries jumps on earnings report Continue reading...
- 06/08/2020
|
Tracking Al Gore's Generation Investment Management Portfolio - Q1 2020 Update
- Generation Investment Management’s 13F portfolio value decreased from $15.64B to $14.09B this quarter. They added Palo Alto Networks, Gartner, and Trimble, whil
- 06/05/2020
|
Baxter to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast
- Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast on Tuesday, June 9, 2020. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 9:40 a.m. Eastern Time.
- 06/02/2020
|
Impact of COVID-19 on Infection Surveillance Solutions Systems Market to See Huge Growth by 2026 | BD., Premier, Wolters Kluwer, Baxter, GOJO Industries, Inc., Atlas Development Corporation
- Jun 02, 2020 (CDN Newswire via Comtex) --
Global Infection Surveillance Solutions Systems market research report considers recent developments, product...
- 06/02/2020
|
China to cut clean coal from green bond eligibility list
- Major development with potential big flow-on impact on financing for investments, says CBI chief #china #climatebondsinitiative #greenprojectscatalogue
- 06/02/2020
|
Baxter to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast
- Baxter International Inc. (NYSE:BAX), a leading global medical products company, will present at the Goldman Sachs 41st Annual Global Healthcare Confe
- 06/02/2020
|
May Was Bad for Dividends. But Here are 11 Big Companies That Raised Their Payouts.
- The increases came in a month when many other companies said they would maintain their payouts at current levels or, worse, suspend them.
- 06/01/2020
|
Tracking Larry Robbins' Glenview Capital Management Portfolio - Q1 2020 Update
- Glenview Capital Management’s 13F portfolio value decreased around two-thirds from $11.42B to $3.68B this quarter. The number of positions decreased from 50 to
- 06/01/2020
|
TriSalus Appoints Rajesh B. Mistry Chief Financial Officer
- TriSalus Life Sciences announced the appointment of Rajesh B. Mistry as Chief Financial Officer.
- 06/01/2020
|
Why Is Baxter (BAX) Up 1.4% Since Last Earnings Report?
- Baxter (BAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- 05/30/2020
|
Hedge Funds Are Flocking Into Baxter International Inc. (BAX)
- In this article you are going to find out whether hedge funds think Baxter International Inc. (NYSE:BAX) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]
- 05/29/2020
|
Vaxcyte Begins U.S. IPO Effort (Pending:PCVX)
- Vaxcyte has filed to raise $100 million in an IPO, although the final figure may differ. The firm is developing vaccines for a number of disease conditions. PCV
- 05/29/2020
|
European Hospital Supplies Market Growth, Trends and Forecasts 2020-2025 - ResearchAndMarkets.com
|
Al Gore Sells Credicorp and Adds 3 New Holdings
- Former US vice president's firm releases 1st-quarter portfolio Continue reading...
- 05/27/2020
|
ALE Responds and Baxter Weighs in on Chrimar Bid for High Court to Consider ‘Soundness’ of Fresenius/ Simmons Principle
- One more amicus, Baxter International, has submitted its brief in support of Chrimar, followed by ALE’s brief in opposition to the petition, in Chrimar System Inc.'s petition to the Supreme Court for review of the 'soundness' of the Fresenius/ Simmons preclusion principle.
- 05/27/2020
|
Point72 Asset Management Buys Micron Technology, Baxter
- Firm's largest buys of the 1st quarter Continue reading...
- 05/27/2020
|
Patent Filings Roundup: Video Gambling Games Going to the Dogs, The Queen’s Cherries, and a Tale of Bankruptcy and Patent Infringement in Cinema Stadium Seating
- With 27 new Patent Trial and Appeal Board (PTAB) filings—25 inter partes reviews (IPRs), one post grant review (PGR) and one covered business method review (CBM), the first in months—this week’s numbers rested roughly within the new normal, with district court complaints flatlining at around 70 (i.e., 68 this week).
- 05/27/2020
|
Baxter Receives CE Marking for Evo IQ Syringe Infusion System
- Baxter (BAX) receives the CE marking and regulatory approval for the Evo IQ Syringe Infusion system that will help in optimizing efficiency for clinicians.
- 05/27/2020
|
RMB Capital Management LLC Purchases 265 Shares of Baxter International Inc (NYSE:BAX)
- RMB Capital Management LLC increased its stake in Baxter International Inc (NYSE:BAX) by 5.1% during the first quarter, Holdings Channel.com reports. The firm owned 5,432 shares of the medical instruments supplier’s stock after purchasing an additional 265 shares during the quarter. RMB Capital Management LLC’s holdings in Baxter International were worth $441,000 as of its […]
- 05/27/2020
|
Point7— Asset Management Buys Micron Technology, Baxter
|
Global Prepackaged Medical Kits and Tray Market 2020 Key Players Analysis, Segmentation, Industry Size, Growth, Trend and Forecast by 2026
- May 25, 2020 (CDN Newswire via Comtex) --
Global Prepackaged Medical Kits and Tray Market 2020 by Company, Regions, Type and Application, Forecast to 2026...
- 05/26/2020
|
COVID-19 Impact on Critical Care Device Market by Device and Region - Global Forecast to 2021 - ResearchAndMarkets.com
|
Inhalation Anesthesia Market Share, Growth to record over US $1.9 billion by 2025
- May 25, 2020 (Market Insight Reports) --
Selbyville, Delaware According to Market Study Report, Inhalation Anesthesia Market provides a comprehensive...
- 05/25/2020
|
European Medical Devices Market Worth $61.4 Billion by 2025 - Exclusive Report by MarketsandMarkets™
- CHICAGO, May 25, 2020 /PRNewswire via COMTEX/ --
CHICAGO, May 25, 2020 /PRNewswire/ -- According to the new market research report "European Medical Devices...
- 05/25/2020
|
Tissue Engineering Market Size Worth $28.9 Billion by 2027 | CAGR: 14.2%: Grand View Research, Inc.
- SAN FRANCISCO, May 25, 2020 /PRNewswire via COMTEX/ --
SAN FRANCISCO, May 25, 2020 /PRNewswire/ -- The global tissue engineering market size is expected to...
- 05/25/2020
|
Global Therapeutic Plasma Exchange Market by Technique, Indication, Gender, End-use and Region - Forecast to 2025 - ResearchAndMarkets.com
|
80 pub quiz questions on TV, politics general knowledge and countries
- We've put together a ready-made lockdown quiz perfect to test your family and friends.
- 05/24/2020
|
United States Market for Durable Medical Equipment 2020-2027 - ResearchAndMarkets.com
|
Medical Nutrition Products Market Current Scenario: who will surpass: Nestle, Vitaflo(R), Hospira
- May 20, 2020 (HTF Market Intelligence via COMTEX) --
A latest survey on Medical Nutrition Products Market is conducted to provide hidden gems performance...
- 05/20/2020
|
Mexico orders probe into alleged graft linked to ex-president
- Mexican President Andres Manuel Lopez Obrador on Wednesday ordered an investigation into allegations the former government irregularly awarded lucrative contracts to a firm reportedly owned by the family of his predecessor, Enrique Pena Nieto. "We have to investigate if President Pena Nieto is involved and see how long the company has been operating, what contracts it received ... if they were awarded directly, through tenders," Lopez Obrador said at his daily press conference. Baxter and Plasti-Esteril were not immediately available to comment.
- 05/20/2020
|
IV Equipment Market Analysis as per the Latest Coronavirus Impact
- May 20, 2020 (Heraldkeepers) --
New York, May 20, 2020: You will get latest updated report as per the COVID-19 Impact on this industry. Our updated reports...
- 05/20/2020
|
Baxter International shares are trading higher after the company received CE marking and regulatory approval from Australia's TGA for its Evo IG Syringe Infusion System.
|
Baxter International Inc. -- Moody's announces completion of a periodic review of ratings of Baxter International Inc.
- Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Baxter International Inc. New York, May 20, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Baxter International Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
- 05/20/2020
|
Baxter Reports Receives CE Marking, Australian Regulatory Approval For Evo IQ Syringe Infusion System
|
Baxter Receives CE Marking and Australian Regulatory Approval for Evo IQ Syringe Infusion System, Building on Smart Pump Platform
- Baxter International Inc. (NYSE:BAX), a leader in innovative technology for medication delivery, today announced CE marking and regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for the Evo IQ Syringe Infusion System. The company expects hospitals in the United Kingdom, Ireland, Greece, Australia and New Zealand to be among the first to receive the new system, with additional countries to follow in a series of planned regulatory submissions.
- 05/20/2020
|
Analysis on Impact of Covid-19- Renal Dialysis Market 2020-2024 | Increasing Number of ESRD Patients to Boost Growth | Technavio
- The renal dialysis market is poised to grow by USD 31.71 bn during 2020-2024, according to Technavio
- 05/20/2020
|
Daniel Loeb Exits Campbell Soup and Trims Baxter in the 1st Quarter
- Third Point’s top 3 sells for the quarter outweigh its top 2 new buys Continue reading...
- 05/18/2020
|
Third Point Exits Campbell Soup, Trims Baxter International
- Firm's largest sales of the 1st quarter Continue reading...
- 05/18/2020
|
Third Point Exits Campbell Soup, Trims Baxter International
|
